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Abstract

ATRX is a chromatin remodeling protein important for neural development, and ATRX
inactivation leads to genomic instability, mitotic defects and TP53-mediated apoptosis. In
the last few years, ATRX mutations were identified in a large proportion of paediatric and
adult gliomas that often coincide with mutations in the tumor suppressor TP53. The present
work shows that combinatorial loss of ATRX and TP53 function in vitro leads to excessive
genomic instability albeit improving cell viability, identifying potential early events in
gliomagenesis. Furthermore, several gene transcripts associated with glioma development
and known oncogenic pathways were significantly upregulated in the Atrx-null neonatal
mouse forebrain. Finally, a mouse model of Atrx and Tp53 deficiency in the mouse CNS
was generated, providing a tool for future investigations.

Keywords: ATRX, Alpha thalassaemia mental retardation X-linked, cancer, glioma,
gliomagenesis, neuroprogenitor cell, NPC, TP53
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CHAPTER 1 – Introduction

1.1

Glioma

Gliomas are the most common primary brain malignancies and constitute a wide and
heterogeneous population of tumours (Furnari 2007). Despite being defined across various
malignancy states – from low-grade, benign tumours to highly aggressive and invasive
glioblastoma multiforme (GBM) tumours – gliomas are extremely challenging to treat in
the clinic because of their infiltrative nature and high tendency for recurrence (Wen 2008).
Recent work has identified numerous genetic and epigenetic alterations that define various
subtypes of glioma (Verhaak 2010). However, the underlying mechanisms of glioma
initiation and progression have yet to be fully elucidated, and this may be achieved through
the development of novel in vitro and in vivo model systems.

1.1.1

Histology and Pathology of Glioma

Classically, gliomas can be categorized based on their histology as astrocytomas,
oligodendrogliomas, or mixed-lineage oligoastrocytomas, and subsequently graded on the
World Health Organization (WHO) scale based on their degree of malignancy (Marumoto
2012). The majority of high grade glial tumours are termed glioblastomas and display
several features of malignancy, including vascularization, necrosis, and pleomorphism.
Glioblastomas can be further subdivided into primary and secondary GBMs based on their
clinical presentation; however, histologically these two tumour subtypes are
indistinguishable. Primary GBMs typically arise de novo in older patients, while secondary
GBMs are most commonly seen in younger patients (below age 45) and develop from lower
grade tumours about 5-10 years following diagnosis (Marumoto 2012).
Contrastingly, low-grade gliomas (LGGs) are classified as grade I or II on the WHO
grading scale and constitute 30-50% of all central nervous system (CNS) solid tumours in
children (Stieber 2001; Louis 2007). Again, LGGs can be histologically categorized into
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pilocytic or low-grade astrocytomas, oligodendrogliomas, or oligoastrocytomas; however,
these tumour types have prolonged survival and reduced recurrence rates compared to their
high-grade counterparts. Low-grade gliomas are also considerably heterogeneous in nature
and often undergo anaplastic dysplasia (Louis 2007).

1.1.2

Key Players in Glioma Pathogenesis

Genetically, both primary and secondary GBMs commonly show alterations in tumour
suppressor protein 53 (TP53), phosphatase and tensin homolog deleted from chromosome
10 (PTEN), and epidermal growth factor receptor (EGFR), including loss or mutation of
either TP53 or PTEN and/or amplification or overexpression of EGFR (Marumoto 2012).
Additionally, both primary and secondary GBMs commonly show abnormal activation of
growth factor signalling, leading to aberrant signalling through the mitogen activated
protein kinase (MAPK) and phosphoinositide-3-kinase (PI3K)-AKT pathways, as well as
cell cycle checkpoint dysregulation, including retinoblastoma protein (pRB) and/or
p16INK4A inactivation (Marumoto 2012).
Until recently, high-grade gliomas (HGGs) – including glioblastoma multiforme and
anaplastic astrocytomas – were distinguished solely by their histological properties.
However, recent evidence indicates that these histological subtypes may represent several
sub-classes of HGG that can be further defined based on their molecular and genetic
profiles. From this, four subtypes of primary GBMs have emerged based on tumour gene
expression/mutation profiles. These subtypes have been termed ‘proneural’, ‘neural’,
‘classical’, and ‘mesenchymal’, and are distinguished by their unique pattern of genetic
changes (Phillips 2006; Verhaak 2010). While two major features in proneural GBM
subtype tumours are alterations in the expression of Platelet Derived Growth Factor Alpha
(PDGFA) as well as point mutations in Isocitrate Dehydrogenase 1 (IDH1), the neural
subtype demonstrates expression of neuron markers like NEFL, GABRA1, SYT1, and
SLC12A5 (Verhaak 2010). Alternatively, classical GBM tumours typically show
amplification of chromosome 7 along with loss of chromosome 10 and overexpression of
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EGFR (Verhaak 2010). Finally, mesenchymal tumours generally show loss of NF1 and/or
PTEN, both of which impact signalling through the AKT pathway (Verhaak 2010).
The underlying genetic mechanisms surrounding LGG pathogenesis have not been
extensively studied; however, mutation of the Isocitrate Dehydrogenase 1 or 2 (IDH1/2)
genes appears to be a common pathogenic initiating event (Sanson 2009; Hartmann 2009;
Ducray 2009) associated with massive changes to the epigenomic landscape (Turcan 2012).
Additionally, coordinated loss of chromosomes 1p and 19q (1p/19q co-deletion) appears to
converge with mutations in IDH1/2 and delineates a prognostically favourable outcome
within oligodendrogliomas and some oligoastrocytomas (Cairncross 1998). Tumours
harbouring intact 1p/19q but mutated IDH1/2 commonly overlap with mutations in TP53
and display a much more diverse genomic landscape (Thon 2012).

1.1.3

TP53 Mutations in Glioma

Alterations in TP53 were one of the first recurrent mutations discovered within gliomas,
and have now become the most common genetic abnormalities observed across the glioma
tumour spectrum. TP53 is a transcription factor that regulates a large number of genes
involved in cell cycle control, DNA damage response, metabolism, cellular senescence,
autophagy and apoptosis (Guimaraes 2002), along with its other non-transcriptional roles
in the regulation of autophagy and apoptosis (Green 2009). The TP53 protein can be
activated by a number of internal and external stimuli, including DNA damage, aberrant
growth factor signalling, oncogene activation, and hypoxia (Vousden 2009). Failure to
activate TP53 in response to tumorigenic stimuli, like DNA damage or oncogene activation,
will prevent the initiation of downstream DNA repair, cellular senescence and apoptotic
pathways which may allow cells to become oncogenic.
The TP53 protein is also pivotal in the regulation of stem cell self-renewal, potency, and
differentiation. In fact, inhibition of the TP53 protein in induced pluripotent stem cells
(iPSCs) caused a 100-fold increase in proliferative capacity (Krizhanovsky 2009) and a
concomitant increase in genetic instability at levels similar to that seen in cancer stem cells
3

(CSCs; Marión 2009). A variety of mouse models harbouring complete loss of Tp53, or
loss of specific codons/exons of Tp53, show increased susceptibility to spontaneous tumour
formation and decreased overall survival (Pohl 1988; Donehower 1992; Jacks 1994).
Deletion of TP53 in conjunction with loss of other tumour suppressor genes or
overexpression of oncogenes further promotes tumour development, progression, as well
as aggressiveness and metastatic potential, specifically in high-grade adult astrocytoma
(Chow 2011). However, in glioma patients, it is uncertain how the loss of TP53 affects
prognostic outcome, as TP53 mutations do not correlate with patient survival or time-torecurrence (Houillier 2006; Weller 2009).
Inhibitors of TP53 have been developed and are beginning to be widely used to examine
the cytotoxic effects of TP53 inhibition both in vitro and in vivo. One such inhibitor, called
Pifithrin-α (PFTα) was originally discovered in a broad screen of approximately 10,000
compounds to inhibit cell death induced by γ-irradiation (Komarov 1999). Although the
complete mechanism of TP53 inhibition has not been explored, studies showed that PFTα
treatment was associated with reduced nuclear, but not cytoplasmic, levels of TP53
(Komarov 1999). This indicates that PFTα acts to modulate the nuclear import and/or
export of TP53, thereby preventing TP53 from binding to its transcriptional targets. PFTα
was later shown to prevent apoptosis in mouse embryonic fibroblasts (MEFs) transformed
with E1a+ras, a cell line that undergoes rapid TP53-mediated apoptosis in response to
treatment with various genotoxic stressors, including doxorubicin, etoposide, UV light, and
γ-irradiation (Komarov 1999). Additionally, PFTα prevented the appearance of apoptotic
cells in doxorubicin-treated human umbilical vein endothelial cells (HUVECs) along with
blocking promoter induction and protein up-regulation of CD95 in response to doxorubicin
treatment (Lorenzo 2002). Following several years of development, new isoforms of PFTα
have been developed. The cyclic form of PFTα (cPFTα) is a more stable analog of PFTα
with similar biological activities and reduced cytotoxicity, and studies have shown that
cPFTα sensitizes wildtype TP53 tumour cells to antimicrotubule agent-induced apoptosis
(Zuco 2008). Thus, these drugs have been described throughout the literature as being
effective and specific inhibitors of the transcriptional activation activities of TP53 and their
use has enabled the discovery of novel TP53 functions in carcinogenesis.
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1.1.4

IDH1/2 Involvement in Glioma Initiation and Progression

Mutations in the Isocitrate Dehydrogenase 1 and 2 (IDH1/2) genes were first identified in
2008 from the analysis of over 20,000 genes in 22 GBM samples (Parsons 2008). Since
then, IDH1 mutations have become an extremely prominent player in gliomagenesis, as
other studies identified IDH1 alterations in up to 80% of grade 2 and 3 gliomas as well as
secondary GBMs (Hartmann 2009; Sanson 2009; Yan 2009; Watanabe 2009; Kanamori
2013). Mutations in IDH2 are also found within the glioma spectrum; however, they arise
at a much lower frequency and are mutually exclusive from IDH1 modifications (Hartmann
2009; Yan 2009).
To date, mutations in IDH1 or IDH2 can be narrowed down to a single amino acid residue
(R132 in IDH1; R172 in IDH2). The R132 residue in IDH1, as well as the analogous R172
residue in IDH2, lies in the active site of the enzyme and is critical for isocitrate binding
(Xu 2004). Mutation at this residue abolishes the ability of IDH to perform its catalytic
activities, resulting in reduced levels of α-ketoglutarate (α-KG) and nicotinamide adenine
dinucleotide phosphate (NADPH; Xu 2004). Exactly how IDH mutation leads to oncogenic
transformation remains unclear; however, recent evidence suggests that mutated IDH is
able to bind and convert α-KG into (R)-2-hydroxyglutarate (2-HG; Dang 2009). Whether
reduced activity of IDH or elevated 2-HG levels leads to tumorigenesis is unknown, but
evidence suggests that the mutated IDH genes act as oncogenes, while 2-HG acts as an
oncometabolite. Regardless of the mechanism, it is known that introduction of mutated IDH
into normal cells leads to increased cellular proliferation, reduced differentiation, and
increased colony formation (Koivunen 2012).
Though mutations in IDH appear to be an early event in oncogenic transformation, further
mutations in other tumour suppressors (like TP53) or genomic instability events (like
1p/19q co-deletion) are necessary for cells to fully gain their oncogenic potential. Within
astrocytic tumours, co-mutation of IDH1 and TP53 is common, with up to 80% of
secondary GBMs and anaplastic astrocytomas harbouring both mutations (Yan 2009). On
the other hand, oligodendrogliomas that harbour 1p/19q co-deletion typically show
5

mutations in IDH1 but not TP53 (Kanamori 2013; Watanabe 2009; Yan 2009). Finally,
although commonly seen alongside mutations that are associated with LGGs and secondary
GBMs, mutations in IDH rarely overlap with alterations common to primary GBMs (like
mutation of EGFR; Watanabe 2009), which is indicative of a role for IDH mutation as an
early event in gliomagenesis, but not as a driver of primary GBM.

1.1.5

ATRX: a new player in Gliomagenesis

Mutations in alpha thalassaemia mental retardation X-linked (ATRX) were first identified
in gliomas through an association with the alternative lengthening of telomeres (ALT)
phenotype (Heaphy 2011) – a telomerase independent mechanism whereby cells can
lengthen their telomeres. ATRX mutations were detected in various tumours of the central
nervous system (CNS), including pediatric GBM (14.3%), adult GBM (7.7%), and
medullobastoma (1.5%) (Heaphy 2011). Other studies used whole exome sequencing of
pediatric GBMs and identified mutations in ATRX in 33.3% of cases, and these mutations
significantly

overlapped

with

alterations

in

TP53

(Schwartzentruber

2012).

Immunostaining of patient tissue microarrays for ATRX in 124 samples identified 35%
lacking detectable ATRX staining, indicative of impaired ATRX transcription/translation
resulting in low or no ATRX protein expression and function (Schwartzentruber 2012).
Thus, these two studies first identified a role for ATRX perturbation in pediatric
glioblastoma multiforme.
Since then, research has delved into the field of both adult and pediatric glioma, and ATRX
mutations have been identified across the glioma landscape (Jiao 2012; Liu 2012; Kannan
2012; Wiestler 2013). Alterations in ATRX were identified by Sanger sequencing in 67%
of WHO grade II astrocytomas, 73% of WHO grade III astrocytomas, 57% of secondary
GBMs, and 68% of mixed oligoastrocytomas (Jiao 2012), and these tumours almost always
showed co-mutation of TP53 and/or IDH1 (Jiao 2012; Liu 2012). Mutations in ATRX were
rare, however, in primary GBMs (4%) (Jiao Y et al 2012). Within LGGs, ATRX mutations
were discovered in three out of four WHO grade II gliomas that harboured IDH mutations,
and this correlated with mutation in TP53 and intact 1p/19q (Kannan 2012). Investigation
6

of another 28 WHO grade II and III gliomas identified ATRX mutations in 43% of samples,
and these mutations again significantly correlated with alteration of IDH and TP53 (Kannan
2012). Collectively, these studies identify ATRX as a potential biomarker for glioma
subtype classification when investigated in combination with IDH, TP53, and 1p/19q
mutation status.

1.2

Alpha Thalassaemia Mental Retardation X-Linked

The ATRX gene lies on the long arm of the X-chromosome (Xq13.3; Fig. 1.1) and spans
approximately 300kb of genomic sequence (Picketts 1996). In humans, the ATRX gene has
been mapped between the gene for Menkes disease (MNK) and the X-chromosome region
DXS56 (Stayton 1994); whereas in mice, the Atrx homolog maps between the
Phosphoglycerate kinase-1 (Pgk1) and X-inactivation specific transcript (Xist) genes (Gecz
1994). This gene gives rise to the large ATRX protein (approximately 280kDa), which
contains an N-terminal ADD (ATRX-DNMT3-DNMT3L) domain as well as a C-terminal
SWI/SNF2-like motif (Fig. 1.1; Picketts 1996). The ADD domain of ATRX shows
homology to the DNMT (DNA methyltransferase) family of proteins (Picketts 1996;
Argentaro 2007) and consists of three regions, including a GATA-like zinc finger, an
imperfect PHD-like zinc finger, and a C-terminal helix that packs together using
hydrophobic interactions (Argentaro 2007). In this way, the ADD domain of ATRX can
bind directly to the tail of histone 3 (H3) using two binding pockets: one that reads
unmethylated lysine 4 (H3K4me0) and one that reads di- or trimethylated lysine 9
(H3K9me2 or H3K9me3) (Iwase 2011; Eustermann 2011). This combinatorial readout,
which is further enhanced by HP1α binding, allows for ATRX recruitment to
heterochromatin (Eustermann 2011). At the other end of ATRX, the SWI/SNF2-like
domain contains an ATPase/helicase motif, and this region is necessary for the nucleosome
remodelling and translocase activity of ATRX (Picketts 1996). ATRX also harbours many
binding sites for various protein-protein interactions (Fig 1.1), including DAXX (death
domain associated protein 6; Tang 2004; Xue 2003), HP1α (heterochromatin-associated
protein 1 alpha; McDowell 1999), and MeCP2 (methyl CpG binding protein 2; Nan 2007).
An additional, truncated isoform of ATRX (called ATRXt) was discovered when
7
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Figure 1.1 Overview of the ATRX gene and protein. (A) Outline of the human X
chromosome and location of the ATRX gene, indicated in red. (B) Schematic of the
ATRX protein including its conserved protein domains (coloured in dark blue) and
protein interaction sites (coloured in red). The yellow line indicates the placement of the
neo cassette in our Atrx floxed mice. (C) Cre/loxP targeting of the Atrx mouse gene. The
top line indicates the wildtype Atrx allele (AtrxWT). The middle line shows the insertion
of loxP target sites flanking exon 18 along with a neo marker (Atrxflox). The bottom line
demonstrates the recombination of Atrx upon Cre recombinase activation in which exon
18 and the neo cassette have been removed (AtrxΔ18Δneo).
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immunoblots using ATRX N-terminal antibodies consistently detected a shorter protein
product of about 180kDa (Bérubé 2000; McDowell 1999). This short isoform results from
an alternative splicing event that leads to the creation of a premature stop codon within
intron 11 (Fig 1.1; Garrick 2004). Due to the truncation, the resulting short polypeptide still
contains the ADD domain but lacks the Swi/Snf C-terminal domain, PML targeting region,
and the interaction sites for DAXX and MeCP2 (Fig 1.1). As expected, ATRXt can localize
to regions of the nucleus dictated by the ADD domain, like pericentromeric
heterochromatin, but is no longer found in PML bodies (Garrick 2004). Biologically, the
function of ATRXt still remains elusive; however, it is predicted that ATRXt may interact
with the full-length ATRX protein (Garrick 2004) and could modulate the activity of ATRX
at heterochromatin.

1.2.1

ATRX and Neuronal Development

ATRX is expressed in the proliferating neuroprogenitor cells of the brain and retina during
development. ATRX exhibits a typical punctate staining pattern that overlaps with
heterochromatic foci (Bérubé 2005), and upon differentiation, ATRX protein levels
increase within the nucleus (Bérubé 2005; Ritchie 2008). Studies over the past decade or
so have determined that incorrect expression or activity of ATRX is clearly detrimental to
development in both humans and mice. Mutations in ATRX in humans results in ATR-X
syndrome (alpha thalassaemia mental retardation, X-linked; OMIM: #30032),
characterized by mild to severe mental retardation, distinct facial dysmorphisms, urogenital
abnormalities, loss of white matter, and α-thalassaemia (Weatherall 1981; Gibbons 2006).
The majority of disease mutations map within the ADD and Swi/Snf domains of ATRX,
resulting in reduced protein expression levels (hypomorphic) rather than a complete lossof-function, which is presumed to be lethal (Gibbons 1995; Picketts 1996).
Study of ATRX gain- and loss-of-function in mice provided insights into the role of ATRX
during development. Examination of ATRX overexpression led to a wide array of
developmental abnormalities, including embryonic lethality and disorganization of the
proliferative neuroepithelium (Bérubé 2002). The few surviving ATRX transgenic pups
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exhibited craniofacial abnormalities and spontaneous seizures (Bérubé 2002). On the other
hand, loss of ATRX in mouse embryonic stem cells (mESCs) resulted in reduced cellular
proliferation and survival (Garrick 2006). Complete ATRX loss in the mouse via early
inactivation at the morula stage prevented the formation of a normal trophectoderm and
resulted in embryonic lethality around E9.5 (Garrick 2006).
To better investigate the loss of ATRX specifically in the developing mouse brain, the
Cre/loxP system was utilized to ensure precise spatial and temporal ablation of ATRX
function (Bérubé 2005). This system incorporates loxP sites flanking exon 18 of Atrx along
with Cre-mediated recombination and silencing of Atrx using a specific Cre-driver line (Fig
1.1). For example, when the Cre recombinase gene is placed under the control of the
Forkhead box G1 (FoxG1) promoter, Cre recombinase expression is confined to the mouse
forebrain beginning at E8.5 (Hebert 2000). As a result of ATRX loss in the developing
telencephalon, a significant increase in apoptosis was observed along with a profound size
reduction of the frontal cortex, hippocampus, and a loss of the dentate gyrus structure
(Bérubé 2005). At birth, ATRX-null male mice are also much smaller in length and weight
than their littermate-matched control male counterparts (Bérubé 2005). This result indicates
the importance of ATRX for the survival of neurons during corticogenesis, as a loss of
ATRX in proliferating cells was succeeded by an increase in TP53 activation along with
downstream TP53 target genes (Seah 2008). Combined loss of ATRX with TP53 in mice
demonstrated a rescue of cell death embryonically; however, overall brain and body size at
birth were not rescued (Seah 2008), indicating that TP53 activation is responsible for some
but not all of the ATRX-null phenotypes observed.

1.2.2

Cellular Functions of ATRX

The finding of an N-terminal nuclear localization signal (NLS) within the ATRX protein
led to the discovery that ATRX is associated with pericentromeric heterochromatin during
all stages of the cell cycle (Bérubé 2000; McDowell 1999). This soon led to the finding that
ATRX is phosphorylated mainly on serine residues and in a cell cycle-dependent manner
(Bérubé 2000). In fact, depletion of ATRX in human HeLa cells (cervical cancer cell line)
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using both stable shRNA constructs and transient small interfering RNA (siRNA) led to
nuclear blebbing, chromosomal bridging, and poorly resolved chromatin during interphase
(Ritchie 2008). Additionally, ATRX-depleted HeLa cells exhibited prolonged
prometaphase to metaphase transitions during mitosis, leading to an overall lengthening of
the time required to complete mitosis compared to ATRX wildtype HeLa cells (Ritchie
2008). This was accompanied by abnormal sister chromatid congression to the metaphase
plate, reduced sister chromatid cohesion at metaphase, and chromosome decondensation
(Ritchie 2008). These results were further validated in vivo where DAPI staining revealed
pyknotic nuclei, micronuclei, and misaligned chromosomes within the hippocampal hem,
the hippocampal primordium, and the dorsal cortical neuroepithelium in embryonic brain
sections (Ritchie 2008). Furthermore, ATRX is required for proper meiotic spindle
organization and chromosome alignment during metaphase II in mouse oocytes (De La
Fuente 2004; Ritchie 2014). Thus, ATRX is necessary for the maintenance, organization,
and architecture of the chromosomes at the metaphase plate in both meiosis and mitosis.
During S-phase, ATRX has been shown to localize to G-rich tandem repetitive DNA like
G-quadruplexes, satellite repeats, and telomeres, and ATRX depletion results in delays in
S-phase and replication stress (Wong 2010; Huh 2012; Leung 2013; Watson 2013). In
myoblasts, ATRX depletion led to alterations in cell cycle checkpoint proteins (p107,
cyclin E, cyclin A, and p27), along with TP53 accumulation (Huh 2012). ATRX loss in
mESCs, mouse embryonic fibroblasts (MEFs) and somatic cell lines was also associated
with sensitivity to hydroxyurea (HU) and aphidicolin (APH) genotoxic treatments, but not
to γ-irradiation (Clynes 2014; Watson 2013; Leung 2013), indicating that ATRX-null cells
demonstrate a specific sensitivity to drugs that induce replication fork stalling. Replication
stress was observed in conjunction with significant increases in genomic instability and
DNA damage (Clynes 2014; Leung 2013; Watson 2013), along with ATRX localization to
DNA double-stranded break (DSB) sites (Leung 2013) and increased fork stalling during
replication (Leung 2013; Watson 2013; Clynes 2014).
Significant increases in DNA damage were also observed in the ATRX-null embryonic
telencephalon and in the neonatal hippocampus (P0.5), which remains proliferative at this
timepoint (Watson 2013). However, by postnatal day 7 (P7), DNA damage was no longer
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present in both control and ATRX-null brains (Watson 2013), suggesting that endogenous
DNA damage from ATRX loss occurs primarily in replicating cells. Interestingly, the cells
in the embryonic telencephalon that harboured γH2A.X foci also showed staining for
cleaved caspase 3 (AC3), a canonical marker for apoptosis activation (Watson 2013),
indicating that cell death is likely a downstream consequence of DNA damage
accumulation. Assessment of DNA DSBs in ATRX/TP53 compound mutant mice
demonstrated a further increase in γH2A.X immunostaining embryonically (Watson 2013),
along with a rescue of cell death in the hippocampal hem and basal telencephalon at E13.5
(Seah 2008). This result demonstrates that ATRX loss is associated with increased genomic
instability that leads to TP53 stabilization and activation of its downstream apoptotic
pathways. Thus, ATRX is necessary for proper mitotic and meiotic integrity, as well as for
maintaining chromatin stability and architecture, particularly during S-phase.

1.2.3

ATRX and Histone Variants

In addition to its ability to target heterochromatin by directly binding to histone tails, ATRX
also influences the histone composition of chromatin. Firstly, recent research identified a
link between ATRX and a histone variant known as macroH2A (Ratnakumar 2012).
MacroH2A is typically associated with transcriptionally inert DNA, and is frequently found
within heterochromatin (Zhang 2005). ATRX was found to interact with macroH2A in a
chromatin-free cellular fraction, and loss of ATRX resulted in altered levels of macroH2A
(Ratnakumar 2012). Targeted knockdown of ATRX in HEK293 cells (human embryonic
kidney cells) led to a global increase in macroH2A levels in chromatin, but not total cellular
levels, indicating a role for ATRX as a negative regulator of macroH2A incorporation into
chromatin (Ratnakumar 2012). Chromatin immunoprecipitation (ChIP) analysis identified
increased levels of macroH2A at the telomeres upon loss of ATRX, as well as an
accumulation at the α-globin gene cluster (Ratnakumar 2012). While still unclear, ATRXmediated prevention of macroH2A deposition at telomeres may act to ensure telomeric
integrity.
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In addition to its role with macroH2A, ATRX also works with its binding partner DAXX
to mediate histone 3.3 (H3.3) deposition into pericentric, telomeric and ribosomal repeat
chromatin (Drané 2010; Goldberg 2010). H3.3 is a replication-independent histone variant
predominantly associated with active and open chromatin (Loyola 2006), while
phosphorylation of H3.3 at serine 31 (H3.3S31P) is enriched in heterochromatin and acts
as a mitosis-specific marker (Hake 2005). During H3.3 deposition, DAXX acts as a highly
specific histone chaperone that can discriminate between H3 isoforms H3.1, H3.2, and H3.3
(Drané 2010). ATRX can subsequently bind with DAXX/H3.3 and target this complex to
repetitive sequences to enhance H3.3 deposition (Drané 2010; Lewis 2010). Remodeling
assays also identified the ability of the ATRX-DAXX complex to successfully mobilize
H3.3-containing nucleosomes along DNA templates (Lewis 2010).
At the telomeres, ATRX has been shown to colocalize with H3.3 in mES cells, and ATRX
knockdown led to a significant increase in telomere induced dysfunction foci (TIF; a
marker for DNA damage at the telomeres identified by γH2A.X staining) as well as an
extreme reduction of HP1α localization (Wong 2010). ATRX-null ESCs exhibit an extreme
loss of H3.3 at the telomeres but maintain the ability of DAXX to associate with H3.3,
indicating that ATRX is not necessary for the interaction between DAXX and H3.3 but
may be necessary for H3.3 localization to telomeres (Lewis 2010). In contrast, DAXX-null
ES cells showed no interaction between ATRX and H3.3 and showed no change in H3.3
incorporation at telomeres, indicating that DAXX mediates the H3.3-ATRX interaction but
is not required for specific H3.3 deposition at telomeres (Lewis 2010).
Further studies in ATRX-null myoblasts identified a significant increase in DNA damage
at the telomeres as well as increased levels of telomere bridging, duplications and merging
(Huh 2012). This result is further supported by ATRX-null primary neuroprogenitor cells
(NPCs) which showed a significant increase in γH2A.X staining at the telomeres along with
increased telomere-centromere/telomere-telomere fusions (Watson 2013). Loss of
telomeric integrity is commonly associated with replicative disruption at the telomeres
(Sampathi 2011), and G-rich DNA sequences, like telomeres, have been recently shown to
form G-quadruplex (G4) structures which are difficult to replicate (Wu 2010). ATRX has
been demonstrated to bind to G-quadruplexes, and may potentially help to resolve these
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secondary DNA structures during cellular replication (Watson 2013; Levy 2014). Thus, it
appears that ATRX is required for telomere stability and integrity, and this could be due to
its roles in facilitating replication fork bypass within these G-rich regions.

1.3

ATRX and Cancer

Mutations in chromatin remodeling proteins are not common alterations in the pathology
of cancer; nevertheless, ATRX mutations have recently become a hot topic in the field of
cancer biology. After cataloguing the outcomes of ATRX loss within the cell, however, it
is clear to see how the loss of ATRX function could allow for the transformation of cells
towards tumorigenesis. Not only does ATRX loss correlate with replication stress (Clynes
2014; Watson 2013) and mitotic defects (Ritchie 2008; Ritchie 2014), ATRX-null cells
also show significant increases in DNA damage both across the genome (Clynes 2014;
Watson 2013) as well as specifically at the telomeres (Huh 2012; Wong 2013; Watson
2013). Finally, ATRX loss also leads to an increase in TP53-mediated cell death following
the accumulation of DNA damage (Watson 2013; Conte 2012). These phenotypes are well
known hallmarks of tumorigenesis, and combinatorial alterations in ATRX and other tumor
suppressors or oncogenes, like TP53 and IDH1/2, may reveal an underlying genetic
mechanism for some subtypes of glioma and neuroendocrine tumours.

1.3.1

Early Findings for ATRX Loss in Tumorigenesis

Gene expression profiling of de novo childhood acute myeloid leukemia (AML) patients
first identified ATRX loss of expression as a predictor of patient outcome (Lacayo 2004).
Mutations in Fms-like tyrosine kinase 3 (FLT3) are a known prognosticator of poor
outcome in AML patients, but further diagnostic markers were needed to distinguish
between patients who were at high-risk for treatment failure versus those who were not.
Among those patients who harboured FLT3 mutations, high expression of Runt related
transcription factor 3 (RUNX3) and low expression of ATRX correlated with worse
outcome and were more likely to resist treatment (Lacayo 2004). On the contrary, patients
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with higher ATRX expression demonstrated a more favourable outcome (Lacayo 2004).
Thus, this was the first study to identify ATRX expression levels as a predictor of patient
prognosis during tumorigenesis.

1.3.2

ATRX Loss in Neuroendocrine Tumours

Several years after the finding of ATRX mutations in AML patients, alterations in ATRX
were discovered again in a significant population of pancreatic neuroendocrine tumours
(panNETs; Jiao 2011). PanNETs are the second most common pancreatic malignancy with
a ten-year survival rate of only 40% (Fendrich 2009). Currently, surgical resection of these
tumours is the front-line of treatment, but many patients present with unresectable tumours
or extensive metastatic disease which is not responsive to current medical therapies
(Fendrich 2009). Whole-exome sequencing was used to identify commonly mutated genes
within a subset of panNETs, and 17.6% harboured mutations in ATRX, 25% had alterations
in DAXX, and 3% showed TP53 mutations (Jiao 2011). They concluded that mutations in
the DAXX/ATRX pathway are the second most common alteration after mutations in
Multiple endocrine neoplasia type 1 (MEN1), and ATRX mutations were most commonly
insertion/deletions leading to frameshifts within the resulting polypeptide (Fig 1.2; Jiao
2011). Additionally, DAXX and ATRX alterations were mutually exclusive, and both
correlated with an earlier age of diagnosis as well as better overall patient survival (Jiao
2011). In fact, 100% of patients with metastatic disease and mutations in DAXX/ATRX and
MEN1 survived at least 10 years, versus over 60% of patients without these mutations
succumbing to their tumours within five years of diagnosis (Jiao 2011). This may indicate
that ATRX/DAXX mutations could define a molecular subgroup of panNETs and may serve
to aid prognosis and prioritize patients for treatment.
Subsequent studies of panNETs identified further alterations in ATRX and DAXX
expression. Firstly, immunohistochemical analysis of well-differentiated neuroendocrine
carcinomas (NECs), also considered panNETs, demonstrated a loss of ATRX nuclear
staining in 36.4% of tumours and a loss of DAXX staining in 9.1% (Yachida 2012). Again,
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Figure 1.2 Overview of mutations identified within the ATRX gene in various
glioma/panNET patient studies. Triangles represent frameshift mutations, circles
denote nonsense mutations, and squares signify missense mutations. Symbols coloured
in red were mutations described in Jiao 2012 (glioma), symbols in blue were mutations
described in Schwartzentruber 2012 (pediatric GBM), and symbols in green denote
mutations described in Jiao 2011 (panNETs).
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loss of ATRX and DAXX immunostaining was mutually exclusive in these tumours;
however, immunostaining for both ATRX and DAXX was intact in the small- and largecell NECs investigated, which are not considered to be panNETs (Yachida 2012). These
findings identify panNETs as genetically distinct entities from other pancreatic neoplasms,
and that ATRX and/or DAXX mutation status may aid in the distinction between pancreatic
tumour subtypes. More recently, a large panNET sample collection (243 patient samples
across a variety of hospitals) identified a loss of DAXX in 15% and a loss of ATRX in 28%
of samples, with only two samples harbouring a loss of both proteins (Marinoni 2014). Loss
of ATRX/DAXX was also shown to correlate with chromosomal instability (CIN), which is
a characteristic of malignant panNETs (Marinoni 2014). Prognostically, in contrast to the
findings by Jiao (2011), Marinoni (2014) correlated ATRX/DAXX loss as a predictor of
inferior outcome, and did not find a correlation with age of diagnosis. It is evident that loss
of ATRX/DAXX defines a biologically specific subgroup of panNETs, but it is unclear
whether ATRX/DAXX mutations are prognostically useful to predict patient outcome.
Finally, a study by Chen (2013B) examined neuroendocrine tumours originating from
various organ systems, including gastric, duodenal, rectal, pancreatic, and pulmonary
tissues. Immunostaining for ATRX and DAXX showed loss of these proteins in at least one
sample within neuroendocrine tumours (NETs) from all organs examined (Chen 2013B).
For example, loss of nuclear labelling of either ATRX or DAXX was found in 16.1% of
lung NETs, 7.3% of stomach NETs, 10.9% of duodenum NETs, 51% of panNETs, and
14.6% of rectal NETs; however, no samples showed loss of staining for both proteins (Chen
2013B). Therefore, loss of ATRX and/or DAXX may not only be relevant to pancreatic
lesions, but can also be found within neuroendocrine tumours across many organ systems.

1.3.3

ATRX Mutations Across the Glioma Spectrum

Mutations in ATRX are highly prominent across the glioma tumour landscape (Table 1.1).
First associations linked mutations in ATRX to pediatric glioblastoma multiforme, where
14.3% of samples harboured alterations in the ATRX gene along with 0% showing mutation
in DAXX (Heaphy 2011). This study also examined the U2-OS osteosarcoma cell line and
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Table 1.1 List of ATRX mutations identified in cancers within the literature.

Tumor Type, Grade

Mutation

Diffuse Astrocytoma, II
Diffuse Astrocytoma, II
Diffuse Astrocytoma, II
Diffuse Astrocytoma, II
Anaplastic Astrocytoma, III
Anaplastic Astrocytoma, III
Anaplastic Astrocytoma, III
Anaplastic Astrocytoma, III
Anaplastic Astrocytoma, III
Anaplastic Astrocytoma, III
Anaplastic Astrocytoma, III
Anaplastic Astrocytoma, III
Anaplastic Astrocytoma, III
Anaplastic Astrocytoma, III
Anaplastic Astrocytoma, III
Oligoastrocytoma, II
Oligoastrocytoma, II
Oligoastrocytoma, II
Oligoastrocytoma, II
Oligoastrocytoma, III
Oligoastrocytoma, III
Oligoastrocytoma, III
Oligoastrocytoma, III
Oligoastrocytoma, III
Oligoastrocytoma, III
Oligodendroglioma, II
Oligodendroglioma, III
High Grade Glioma
High Grade Glioma
High Grade Glioma
High Grade Glioma

p.E1702*
p.K971fs
p.R808*
p.F2113fs
p.R781*
p.R2197C
p.E2265A
p.E2277A
p.L1602*
p.D789V
p.S118fs
p.R418*
p.S1387*
p.R808*
p.K1332fs
p.R1426*
p.K1332fs
p.R418*
p.K2283splice
p.R781*
p.G1937E
p.Y2083C
p.R1426*
p.E935*
p.E884D
p.D1051E
p.G2075R
p.F2113fs
p.D1791H
p.T1610R
p.D2144G

Mutation
Type
Nonsense
Frameshift
Nonsense
Frameshift
Nonsense
Missense
Missense
Missense
Nonsense
Missense
Frameshift
Nonsense
Nonsense
Nonsense
Frameshift
Nonsense
Frameshift
Nonsense
Splice Variant
Nonsense
Missense
Missense
Nonsense
Nonsense
Missense
Missense
Missense
Frameshift
Missense
Missense
Missense
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Reference
Cryan, J.B., et al. 2014

Huether, R., et al. 2014

High Grade Glioma
Neuroblastoma
Neuroblastoma
Neuroblastoma
Neuroblastoma
Neuroblastoma
Adrenocortical Carcinoma
Adrenocortical Carcinoma
Adrenocortical Carcinoma
Osteosarcoma
Osteosarcoma
Osteosarcoma
Osteosarcoma
Osteosarcoma
Osteosarcoma
Osteosarcoma
Osteosarcoma
Cutaneous Melanoma
Cutaneous Melanoma
Cutaneous Melanoma
Cutaneous Melanoma
Cutaneous Melanoma
Cutaneous Melanoma
Cutaneous Melanoma
Cutaneous Melanoma
Cutaneous Melanoma
Cutaneous Melanoma
Cutaneous Melanoma
Cutaneous Melanoma
Cutaneous Melanoma
Cutaneous Melanoma
Cutaneous Melanoma
Cutaneous Melanoma
Cutaneous Melanoma
Cutaneous Melanoma
Cutaneous Melanoma
Cutaneous Melanoma

p.R188*
p.L407F
p.A1690D
p.E555*
p.R2188Q
p.E426fs
p.R2164S
p.Q811*
p.E2253*
p.Y266*
p.D1383fs
p.R1803C
p.S213*
p.Y266*
p.D1383fs
p.L1755V
p.R1803C
p.E453K
p.R444Q
p.H756Y
p.S334F
p.D1263E
p.A1790fs
p.D1487N
p.E2050K
p.S342F
p.K1936R
p.S925F
p.M1005I
p.R2150I
p.E2351*
p.L639F
p.E641K
p.E2333K
p.E1258*
p.R2153C
p.S576L

Nonsense
Missense
Missense
Nonsense
Missense
Frameshift
Missense
Nonsense
Nonsense
Nonsense
Frameshift
Missense
Nonsense
Nonsense
Frameshift
Missense
Missense
Missense
Missense
Missense
Missense
Missense
Frameshift
Missense
Missense
Missense
Missense
Missense
Missense
Missense
Nonsense
Missense
Missense
Missense
Nonsense
Missense
Missense
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Chen, X., et al. 2014

Qadeer, Z.A., et al. 2014

Cutaneous Melanoma
Cutaneous Melanoma
Cutaneous Melanoma
Anaplastic Astrocytoma
Glioblastoma, IV
Pilocytic Astrocytoma
PanNET
PanNET
PanNET
PanNET
PanNET
PanNET
Oligoastrocytoma, II
Oligoastrocytoma, II
Oligoastrocytoma, II
Astrocytoma, II
Astrocytoma, II
Astrocytoma, II
Astrocytoma, III
Astrocytoma, III
Astrocytoma, III
Glioblastoma, IV
Glioblastoma, IV
Glioblastoma, IV
Glioblastoma, IV
Glioblastoma, IV
Oligodendroglioma, II
Oligodendroglioma, II
Astrocytoma, II
Astrocytoma, II
Astrocytoma, II
Astrocytoma, III
Astrocytoma, III
Astrocytoma, III
Astrocytoma, III
Astrocytoma, III
Astrocytoma, III

p.L2069F
p.P657K
p.P97S
p.S871*
p.K923*
p.E991K
p.E990*
p.L1645*
p.S2017P
p.R2188Q
p.R2197C
p.F2113fs
p.R1426*
p.R907*
p.E1010fs
p.L639fs
p.K1001fs
p.E991fs
p.K1018fs
p.R1302fs
p.R221K
p.Y187*
p.R1504*
p.R1803H
p.R2153C
p.W263*
p.R221M
p.R1514*
p.Q292*
p.E533*
p.R808*
p.R781*
p.S788*
p.R808*
p.V2189L
p.R937*
p.Y1115*

Missense
Missense
Missense
Nonsense
Nonsense
Missense
Nonsense
Nonsense
Missense
Missense
Missense
Frameshift
Nonsense
Nonsense
Frameshift
Frameshift
Frameshift
Frameshift
Frameshift
Frameshift
Missense
Nonsense
Nonsense
Missense
Missense
Nonsense
Missense
Nonsense
Nonsense
Nonsense
Nonsense
Nonsense
Nonsense
Nonsense
Missense
Nonsense
Nonsense
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Aihara, K., et al. 2014
Zhang, J., et al. 2013
Pugh, T.J., et al. 2013

Kannan, K., et al. 2012

Jiao, Y., et al. 2012

Astrocytoma, III
Astrocytoma, III
Astrocytoma, III
Astrocytoma, III
Oligoastrocytoma, II
Oligoastrocytoma, III
Oligoastrocytoma, III
Oligoastrocytoma, III
Neuroblastoma
Neuroblastoma
Neuroblastoma
Neuroblastoma
Neuroblastoma
Glioblastoma, IV
Glioblastoma, IV
Glioblastoma, IV
Glioblastoma, IV
Glioblastoma, IV
Glioblastoma, IV
Glioblastoma, IV
Glioblastoma, IV
Glioblastoma, IV
Glioblastoma, IV
Glioblastoma, IV
Glioblastoma, IV
Glioblastoma, IV
Glioblastoma, IV
Glioblastoma, IV
Glioblastoma, IV
Glioblastoma, IV
Glioblastoma, IV

p.S125*
p.T1747K
p.A1804P
p.L253*
p.G551*
p.E2172G
p.R1426*
p.R1739*
p.L407F
p.K425fs
p.E555*
p.A1690D
p.R2188Q
p.E1757*
p.K1057fs
p.R1739*
p.M1800T
p.C1122fs
p.S1394fs
p.E1757*
p.H2254R
p.R2111*
p.G1589V
p.R1426*
p.K1584fs
p.N2443D
p.R1302fs
p.D2136N
p.W263*
p.R2153C
p.R1803H

Nonsense
Missense
Missense
Nonsense
Nonsense
Missense
Nonsense
Nonsense
Missense
Frameshift
Nonsense
Missense
Missense
Nonsense
Frameshift
Nonsense
Missense
Frameshift
Frameshift
Nonsense
Missense
Nonsense
Missense
Nonsense
Frameshift
Missense
Frameshift
Missense
Nonsense
Missense
Missense
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Cheung, N.K., et al. 2012

Schwartzentruber, J., et al.
2012

Heaphy, C., et al. 2011

identified a homozygous deletion of exons 2 to 19 within ATRX (Heaphy 2011).
Schwartzentruber (2012) surveyed four pediatric GBMs that harboured mutations in the
histone variant H3.3. Two recurrent mutations were found, G34R and K27M, both of which
lie near the tail of the protein that undergoes important post-translational modifications
involved with transcriptional repression or activation. Interestingly, all four of these
samples also harboured mutations in ATRX that may indicate an underlying dysfunction in
the ATRX/DAXX/H3.3 histone deposition pathway. Whole-exome sequencing analysis
was performed in 42 additional pediatric GBMs and identified ATRX/DAXX/H3.3
mutations in 50% of samples (15/42 H3.3; 14/42 ATRX; 2/42 DAXX) (Schwartzentruber
2012). The majority of ATRX mutations were insertions/deletions leading to frameshifts,
followed by nonsense and missense mutations, and these mutations localized either within
the C-terminal SWI/SNF2 domain of ATRX or led to a truncation of the protein upstream
of this domain (Fig 1.2; Schwartzentruber 2012). Notably, mutations in ATRX and H3.3
overlapped significantly with mutations in TP53, and eight samples had mutations in all
three genes (Schwartzentruber 2012). These data indicate a central role for the
ATRX/DAXX/H3.3 axis in normal cellular morphology, and perturbation of this axis may
underlie the pathology of a subset of pediatric GBM.
Research was soon extended into adult glioma samples, including WHO grade II and III
astrocytomas and oligodendrogliomas, WHO grade III and IV anaplastic astrocytomas,
oligoastrocytomas, and WHO grade IV primary and secondary GBMs. For example,
mutations in ATRX were identified in 93 out of 363 (26%) gliomas samples ranging across
all age groups and tumour grades (Jiao 2012). Specifically, ATRX alterations were found in
67% of grade II astrocytomas, 73% grade III astrocytomas, 57% secondary GBMs, 68%
oligoastrocytomas, and 20% pediatric GBMs (Jiao 2012). The majority of ATRX mutations
in pediatric GBMs clustered again in the C-terminal SWI/SNF2 domain, while adult
gliomas displayed an even distribution across the ATRX gene; however, both adult and
pediatric gliomas showed a bias towards frameshift and nonsense mutations (Fig. 1.2; Jiao
2012). Another study identified ATRX mutations by Sanger sequencing in 47.8% of adult
glioma samples distributed across age and subtype, with again the majority of mutations
being insertions/deletions leading to frameshift mutations in the ATRX polypeptide (Liu
2012). Further immunohistochemical staining for ATRX in another 96 samples showed a
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loss of nuclear ATRX staining in 32% of adult glioma samples, while ATRX staining
remained intact in 34 pilocytic astrocytomas (Liu 2012). Finally, a study that examined
low-grade gliomas identified ATRX mutations in 12/32 samples ranging across grade II and
III astrocytomas and oligoastrocytomas (Kannan 2013). Thus, it is clear that ATRX
mutations represent a recurring abnormality not only in pediatric GBM, but also in adult
gliomas across the tumour spectrum.
Worthy of note is the frequent overlap of ATRX mutations with mutations in other genes,
like TP53 and IDH1/2. One study identified 100% of grade II astrocytomas, grade III
astrocytomas, and grade IV secondary GBMs that harboured ATRX mutations also showed
alteration of IDH, and 94% showed alteration of TP53 (Jiao 2012). Conversely, ATRX
mutations were mutually exclusive from mutations in Homolog of Drosophila capicua
(CIC) as well as 1p/19q co-deletion (Jiao 2012). Furthermore, out of 51 samples with ATRX
mutations, 47 samples had concurrent mutations in IDH1/2, and within this population of
IDH-mutated tumours, ATRX mutations were associated with tumours that also harboured
alterations in TP53 (Liu 2012). Lastly, Kannan (2013) identified 25% of adult glioma
samples distributed across age and subtype that harboured all three mutations (IDH1,
ATRX, and TP53). Taken together, these findings reveal a strong overlap between ATRX
mutations and alteration of IDH and/or TP53, signifying that loss of ATRX alone is unlikely
to direct tumorigenesis and requires additional alteration of known tumour
suppressors/oncogenes to drive carcinogenesis.

1.3.4 Association of ATRX Mutations and Alternate Lengthening of Telomeres
(ALT)
Cells undergoing tumorigenic transformation have the difficult job of acquiring
immortality and this requires counteracting the gradual telomeric attrition that accompanies
semi-conservative DNA replication. To do this, most carcinogenic cells will reactivate the
telomerase enzyme, which is a ribonucleoprotein that can add TTAGGG nucleotides to the
ends of chromosomes mainly through the activity of its catalytic subunit TERT (telomerase
reverse transcriptase) (Morin 1989; Harley 2008; Günes 2013). Approximately 10-15% of
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tumours, however, do not reactivate telomerase and instead use a mechanism called
alternative lengthening of telomeres to maintain the length of their telomeres using
homologous recombination mechanisms (Bryan 1995; Conomos 2012). Cells that have
activated the ALT pathway exhibit numerous characteristics that are distinct from cells that
express the telomerase subunit TERT. Differences include telomere length heterogeneity
(Bryan 1995), abundant extrachromosomal linear and circular DNA (Ogino 1998), high
frequency of telomeric sister chromatid exchange (T-SCE) events (Bechter 2004), and the
presence of a specific subclass of PML bodies that contain telomeric DNA, shelterin
proteins, and homologous recombination factors (Yeager 1999). Little is known about the
molecular details of the ALT pathway, and even less about how the ALT pathway is
initially activated in cells. Nevertheless, we do know that ALT is commonly associated
with high amounts of genomic instability, especially at the telomeres (Lovejoy 2012), along
with remodeling of the telomere architecture (Conomos 2012), and occurs in a particularly
high fraction of certain tumour types like sarcomas, panNETs and brain tumours.
As we know from loss-of-function studies, ATRX plays a major role in maintaining
telomere stability and structure, particularly during S-phase (Watson 2013; Lovejoy 2012).
Loss of ATRX leads to a significant increase in telomeric DNA damage and telomeric
abnormalities, like bridging and fusions (Watson 2013; Lovejoy 2012). Given this potential
role for ATRX in modulating telomeric chromatin, it is perhaps not surprising that ATRX
mutation in glioma samples was highly correlated with the activation of the ALT pathway
(Heaphy 2011; Schwartzentruber 2012; Jiao 2012; Kannan 2013). Furthermore, evaluation
of mutations in either the ATRX gene or the TERT promoter revealed a mutual exclusivity
of these two events, supporting the strong link between ATRX loss and the activation of
ALT (Killela 2013). Tumours harbouring a loss of ATRX commonly show heterogeneous,
ultrabright telomere FISH (fluorescence in situ hybridization) foci (Heaphy 2011;
Schwartzentruber 2012; Kannan 2013), which is an established marker of ALT activation.
As well, many human ALT cancer cell lines show a loss of ATRX function, though loss of
ATRX alone in normal cell lines was not sufficient to induce ALT activation (Lovejoy
2012). Thus, ATRX is required for the maintenance of the ALT phenotype, while activation
of the ALT pathway likely requires additional genetic or epigenetic changes.
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1.4

Hypothesis and Summary of Findings

ATRX loss of function induces cellular phenotypes that are associated with tumorigenic
conversion, yet it also leads to an increase in TP53-mediated cell death. Therefore, the aim
of this study was to determine whether the deletion of both ATRX and TP53 can prevent
apoptosis but still induce genomic instability in neuroprogenitor cells. I hypothesize that
Atrx deletion in conjunction with the loss of TP53 function both in vitro and in vivo will
lead to cellular phenotypes conducive to tumor development. This hypothesis was
addressed using several mouse models that are described in subsection 2.1.
Chapter 3 describes two in vitro systems that were developed to model the initiation and
progression of glioma in patients harbouring mutations in Atrx and Tp53. These systems
consist of cultured mouse neuroprogenitor cells and take advantage of the Cre/loxP system
to recombine and silence either the Atrx gene alone, in combination with a TP53 inhibitor,
or to silence both the Atrx and Tp53 genes simultaneously. The development and validation
of these systems is described in subsections 3.1 and 3.3, while the phenotypic
characterization of sequential or simultaneous loss of ATRX and TP53 function in cultured
neuroprogenitor cells is described in subsections 3.2 and 3.4, respectively.
Subsection 4.1 assesses available online patient data in correlation with ATRX expression
levels or copy number variation at the ATRX locus. Genetic alteration analysis upon the
loss of Atrx alone in the differentiated cells of the neonatal frontal cortex is examined in
subsection 4.2.1. Finally, subsection 4.2.2 describes an in vivo model system following Atrx
and Tp53 heterozygosity in the murine central nervous system to determine whether
combined Atrx and Tp53 loss in vivo would affect the survival of the mice because of
oncogenic phenotypes in the CNS.
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CHAPTER 2 – Materials and Methods

2.1

Animal Husbandry and Genotyping

Several mouse lines were used throughout the following studies and these are summarized
in Table 2.1. Conditional deletion of Atrx in the mouse forebrain was achieved by crossing
AtrxloxP female mice (129Sv background) with heterozygous FoxG1-Cre recombinase
knock-in males (129Sv/FVBN mixed background). AtrxloxP mice contain loxP sites
flanking intron 18 of Atrx (see Fig. 1.1). The FoxG1-Cre recombinase gene directs
recombination and silencing of Atrx specifically in the mouse forebrain beginning at
embryonic day 8.5 (E8.5; Hebert 2000). Control male animals harbour the FoxG1-Cre
recombinase gene, but lack the AtrxloxP allele (Atrxwt/y Cre+), while experimental male
animals have both the AtrxloxP allele along with the FoxG1-Cre recombinase knock-in gene
(AtrxloxP/y Cre+) (Table 2.1). AtrxloxP mice were kindly provided by D. Higgs (Weatherall
Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom) and
the FoxG1-Cre recombinase mice were provided by R. Slack (Ottawa Hospital Research
Institute, Ottawa, Ontario) from a line originally obtained from S. McConnell (Stanford
University, Stanford, California, USA).
A second approach was taken to achieve conditional deletion of Atrx using the Nestin-Cre
recombinase transgenic driver line (Tronche 1999). The Nestin promoter drives the
expression of Cre recombinase across the entire mouse central nervous system (CNS)
beginning at E11.5. Thus, combination of Nestin-Cre recombinase with the AtrxloxP mice
results in recombination and silencing of Atrx throughout the mouse CNS starting at
embryonic day 11.5. Control female animals carry one copy of the floxed Atrx allele and
one wildtype Atrx allele, and do not carry the Nestin-Cre recombinase gene (AtrxloxP/wt NesCre-). Experimental females still carry one Atrx floxed allele and also harbour the NestinCre recombinase gene (AtrxloxP/wt Nes-Cre+).
To achieve Atrx and Tp53 heterozygosity in the mouse CNS, mice harbouring a Tp53-null
allele (Tp53-/-; Jacks 1994) (Jackson Laboratories) were mated with the AtrxloxP/wt
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Table 2.1 Summary of mouse genotypes used within this thesis.

Genotype

Description

Short Form

Atrxwt/y FoxG1-Cre+

Cre recombinase positive male
control

Cre+ control

AtrxloxP/y FoxG1-Cre+

Atrx-null male experimental

Atrx-null

Atrxwt/y Tp53wt/wt

Wildtype male control

Wildtype

AtrxloxP/y Tp53wt/wt

Atrx floxed, Tp53 wildtype
male control

Atrx floxed

Atrxwt/y Tp53loxP/loxP

Atrx wildtype, Tp53 floxed
male control

Tp53 floxed

AtrxloxP/y Tp53loxP/loxP

Atrx floxed, Tp53 floxed male
experimental

Double floxed

AtrxloxP/wt Nestin-Cre- Tp53+/+

Cre recombinase negative
wildtype female control

Wildtype

AtrxloxP/wt Nestin-Cre+ Tp53+/+

Atrx heterozygous, Tp53
wildtype female control

Atrx het

AtrxloxP/wt Nestin-Cre- Tp53+/-

Atrx wildtype, Tp53
heterozygous female control

Tp53 het

AtrxloxP/wt Nestin-Cre+ Tp53+/-

Atrx heterozygous, Tp53
heterozygous female

Double het
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Nes-Cre+ mice to create AtrxloxP/wt Nes-Cre+ Tp53+/- experimental mice. These mice are
heterozygous for Atrx and are mosaic for ATRX expression within the entire CNS.
Additionally, these mice carry a loss of one Tp53 allele throughout the entire body. Control
animals were also created from these crosses, including fully wildtype mice (AtrxloxP/wt NesCre- Tp53+/+), mice heterozygous for only Atrx (AtrxloxP/wt Nes-Cre+ Tp53+/+) and mice
heterozygous for only Tp53 (AtrxloxP/wt Nes-Cre-T Tp53+/-) (Table 2.1).
To achieve conditional and inducible deletion of both Atrx and Tp53 in vitro, we had to
first generate AtrxloxP/loxP Tp53loxP/loxP double floxed mice. Tp53loxP/loxP mice (Jackson
Laboratories, Bar Harbour, Maine, USA) carry two Tp53 alleles with loxP sites flanking
exons 2 to 10 of the gene (Marino 2000). Tp53loxP/loxP mice were crossed with the previously
described AtrxloxP/loxP mice to eventually generate AtrxloxP/loxP Tp53loxP/loxP double floxed
mice. These mice were used for in vitro studies, and thus mating of AtrxloxP/wt Tp53loxP/wt
females with AtrxloxP/y Tp53loxP/wt males could generate AtrxloxP/loxP Tp53loxP/loxP double
floxed embryos, along with the necessary controls: AtrxloxP/loxP Tp53wt/wt (Atrx floxed),
Atrxwt/wt Tp53loxP/loxP (Tp53 floxed), and Atrxwt/wt Tp53wt/wt (wildtype) embryos (Table 2.1).
For embryonic studies, midday of the day of vaginal plug discovery was considered E0.5.
At scheduled gestational time points, typically E13.5, pregnant dams were euthanized by
CO2 suffocation. For postnatal studies, midday of the day of birth was considered P0.5.
Animals younger than P10 were euthanized by cervical dislocation, and older animals were
euthanized by CO2 suffocation. All animal studies were conducted in compliance with the
regulations of The Animals for Research Act of the province of Ontario, the guidelines of
the Canadian Council for Animal Care and the policies and procedures approved by the
University of Western Ontario Council on Animal Care (Appendix A).
For genotyping, tail or ear notch samples from mice were digested and genomic DNA was
extracted using DirectPCR and proteinase K (Thermo Scientific). DNA from these samples
was then genotyped by PCR using primer sets for Atrx (17F, 18R and neoR), Tp53
(Tp53floxF and Tp53floxR; AM3, AM4 and neoF), Cre (Cre3b and Cre5b), and Sry (SryF
and SryR), as listed in Table 2.2.

30

Table 2.2
List of oligonucleotides used in genotyping, qRT-PCR and in situ
hybridization.

Primers used for genotyping of animals
17F:

5`- AGAACCGTTAGTGCAGGTTCA - 3`

18R:

5`- TGAACCTGGGGACTTCTTTG - 3`

neoR:

5`- CCACCATGATATTCGGCAAG - 3`

Cre3b:

5`- TGACCAGAGTCATCCTTAGCG - 3`

Cre5b:

5`- AATGCTTCTGTCCGTTTGCC - 3`

SryF:

5`- GCAGGTGGAAAAGCCTTACA - 3`

SryR:

5`- AAGCTTTGCTGGTTTTTGGA - 3`

Tp53floxF:

5`- GGTTAAACCCAGCTTGACCA - 3`

Tp53floxR:

5`- GGAGGCAGAGACAGTTGGAG - 3`

AM3:

5`- ATAGGTCGGCGGTTCAT - 3`

AM4:

5`- CCCGAGTATCTGGAAGACAG - 3`

neoF:

5`- GATCGGCCATTGAACAAGAT - 3`

Primers used to amplify cDNA for RT-PCR
Atrx F:

5` - AGAACCGTTAGTGCAGGTTCA - 3`

Atrx R:

5` - TGAACCTGGGGACTTCTTTG - 3`

Gapdh F:

5` - GACAAGCTTCCCGTTCTCAG - 3`

Gapdh R:

5` - GAGTCAACGGATTTGGTCGT - 3`

βactin F:

5` - CTGTCGAGTCGCGTCCACCC - 3`

βactin R:

5` - ACATGCCGGAGCCGTTGTCG - 3`

Cxcl12 F:

5` - GTCCTCTTGCTGTCCAGCTC - 3`

Cxcl12 R:

5` - AGATGCTTGACGTTGGCTCT - 3`

Mmp2 F:

5` - ACCAGAACACCATCGAGACC - 3`

Mmp2 R:

5` - AAAGCATCATCCACGGTTTC - 3`

Mmp14 F:

5` - CCCAAGGCAGCAACTTCAG - 3`
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Mmp14 R:

5` - ATCAGCCTTGCCTGTCACTT - 3`

Igfbp2 F:

5` - CACATCCCCAACTGTGACAA - 3`

Igfbp2 R:

5` - GCTGGGGTTTACTGCACACT - 3`

Gsn F:

5` - TGCTGCCATCTTTACTGTGC - 3`

Gsn R:

5` - AAACTGTCCCAGGACACAGG - 3`

Lox F:

5` - TAGGGCGGATGTCAGAGACT - 3`

Lox R:

5` - CCTTCAGCCACTCTCCTCTG - 3`

Mdk F:

5` - CCTGCAACTGGAAGAAGGAA - 3`

Mdk R:

5` - GAGGTGCAGGGCTTAGTCAC - 3`

ErbB3 F:

5` - TACTGGTGGCCATGAATGAA - 3`

ErbB3 R:

5` - CTCAATGTAAACGCCCCCTA - 3`

FoxC1 F:

5` - AGTTCATCATGGACCGATTC - 3`

FoxC1 R:

5` - TCCTTCACTGCGTCCTTCTT - 3`

FoxC2 F:

5` - ATGTTCGAGAATGGCAGCTT - 3`

FoxC2 R:

5` - GGGCACATCCTTCTTCTTGA - 3`

S100A11 F:

5` - GCATTGAGTCCCTGATTGCT - 3`

S100A11 R:

5` - ATCTAGCTGCCCGTCACAGT - 3`

Ahnak F:

5` - TGAGCAGAGTCCTGCAAAGA - 3`

Ahnak R:

5` - ACTGGGTCACCTCACCAGAC - 3`

Wnt5a F:

5` - GGTGCCATGTCTTCCAAGTT - 3`

Wnt5a R:

5` - CTTCGCACCTTCTCCAATGT - 3`

Wnt7b F:

5` - GCGTCCTCTACGTGAAGCTC - 3`

Wnt7b R:

5` - GGAGTTCTTGCCCGAAGAC - 3`

Fzd7 F:

5` - GCTTCCTAGGTGAGCGTGAC - 3`

Fzd7 R:

5` - CAACCCGACAGGAAGATGAT - 3`

Akt F:

5` - GGCAGGAAGAAGAGACGATG - 3`

Akt R:

5` - CCTGTGGCCTTCTCTTTCAC - 3`

Erk1 F:

5` - TCCTTTTGAGCACCAGACCT - 3`

Erk1 R:

5` - AGCAGATGTGGTCATTGCTG - 3`

Erk2 F:

5` - ACACGCAGCTGCAGTACATC - 3`

Erk2 R:

5` - AACATTCTCATGGCGGAATC - 3`
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Primers used to create DIG-labelled anti-sense RNA probes for ISH
ErbB3 SP6 F: 5` - CGATTTAGGTGACACTATAGAATAGAAGTGTGAGGTGGTCATGGGTAAC - 3`
ErbB3 T7 R: 5` - GTAATACGACTCACTATAGGGCACGAACCCATCGATATTGCTAGAG - 3`
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2.2

Quantitative Real Time PCR (qRT-PCR)

Control and experimental mouse forebrains were dissected at birth (P0.5), tissue was
homogenized, and RNA was extracted using the RNeasy® Mini or Micro Kit (Qiagen).
Extracted RNA was subsequently reverse transcribed into cDNA using the following
conditions: RNA (1ug), DEPC-H2O and random primers were heated for ten minutes at
65°C, and then incubated on ice for two minutes. Following this, 5X first strand buffer,
100mM DTT, 25nM dNTPs, Superscript Reverse Transcriptase, RNA guard and more
DEPC-H2O are added to the reaction mixture and then incubated first for ten minutes at
30°C and then for forty-five minutes at 42°C. Resulting cDNA was quantified and stored
at -20°C. Control reactions omitting reverse transcriptase enzyme were prepared in parallel.
cDNA prepared from extracted RNA was used for qRT-PCR using the primers listed in
Table 2.2. Amplification of cDNA was done by mixing cDNA with primers, H2O and iQTM
SYBR® Green mastermix (BioRad) and placing the reaction mixture under the following
conditions: 30-35 cycles of 95°C for 10 seconds, 55°C for 20 seconds, 72°C for 30 seconds,
and a final melting curve generated in increments of 1°C per plate read. Experiments were
performed on a Chromo-4 thermocycler, and gene expression levels were analyzed with
Opticon Monitor 3 and GeneX (BioRad) software. Gene expression analysis was repeated
in duplicate for each primer set, and all primer data were corrected against β-actin or Gapdh
expression levels as an internal control. To confirm correct gene amplification, 20µL of
qRT-PCR product was size-sorted on a 1.5% agarose gel by electrophoresis.

2.3

In Situ Hybridization

DIG-labelled (dioxygenin; Roche Diagnostics) anti-sense RNA probes were made using
gel extracted cDNA (1ug), T3 5x buffer, RNase Guard (Qiagen), 10X DIG-UTP, T7 RNA
polymerase (Affymetrix) and DEPC-H2O. The resulting DIG-labelled RNA probes, diluted
in hybridization buffer, were mixed and heated at 70°C for 10 minutes, and subsequently
overlaid onto 8µm brain cryosections and incubated overnight at 65°C. Following the
overnight incubation, hybridized cryosections were then washed several times in wash
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buffer and 1x MABT. Slides were then blocked in sheep serum plus blocking solution for
1 hour, and then incubated in anti-DIG antibody diluted in blocking solution overnight at
room temperature. Following anti-DIG incubation, slides were then washed several times
in 1x MABT and prestaining buffer, and subsequently incubated in staining buffer –
including 315µL of NBT and 245µL of BCIP (Roche Diagnostics) – for 4 to 24 hours in
the dark. Once the correct staining end point was achieved, slides were then washed in
various concentrations of ethanol and xylene, and coverslips were placed over stained
sections using Permount mounting medium (Fischer Scientific). Stained and coverslipped
sections were visualized with a Leica CTR 6500 microscope, and images were manipulated
using Volocity® software (PerkinElmer Inc., Massachussets, USA).

2.4

Western Blot Analysis

Fresh tissue or cells in culture were mixed with ice cold RIPA buffer (3mL per gram of
tissue, or 50µL per well of a 4-well plate of cultured cells) and homogenized. Cells in RIPA
buffer were then incubated on ice for 30 minutes, transferred to a cold 1.5 mL Eppendorf
tube, and then spun in a cold centrifuge at 13000 RPM for 20 minutes. The supernatant was
then transferred to a new, cold 1.5mL Eppendorf tube, and the cell pellet was discarded.
Protein concentration was measured using a Bradford assay (BioRad), and protein extracts
were stored at -80°C.
Polyacrylamide gels, including a separating gel (6, 10, 12, or 15%) and a stacking gel (4%),
were made, and protein samples were thawed and denatured at 90°C for 10 minutes. 25µL
of samples in 1x loading buffer were loaded into the gel, along with 8µL of protein ladder
(BioRad), and gels were run at 90V for 30 minutes followed by 125-130V for 2 hours in
1X running buffer. Following protein separation, gels were transferred to nitrocellulose
membranes (BioTraceTM, Pall Life Sciences) at 75V for 2 hours in 1X transfer buffer.
Transferred nitrocellulose membranes were then blocked with 5%-milk-TBST or 5% BSA
for 1 hour, and incubated with the primary antibody diluted in either 5%-milk-TBST or 5%
BSA overnight at 4°C. Following primary antibody incubation, membranes were washed
in 1X TBST and incubated with the secondary antibody diluted in 5%-milk-TBST or 5%
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BSA for 1 hour at room temperature. Membranes were then washed, incubated in ECL
(enhanced chemiluminescence) for approximately 1 minute, and subsequently imaged onto
film using a Konica Minolta SRX-101A developer.

2.5

Immunofluorescence

Brains dissected at birth (P0.5) were embedded in OCT (optimal cutting temperature)
medium, snap frozen in liquid nitrogen, and stored at -80°C. Brains were subsequently
cryosectioned coronally at a thickness of 8uM. Coronal cryosections (Fig. 2.1) were thawed
at room temperature for one hour and subsequently rehydrated in 1X PBS for five minutes.
Antigen retrieval was performed, if necessary, by placing slides in warm sodium citrate and
heated at a low level for ten minutes. Still in sodium citrate, slides were then left to cool for
20 minutes and subsequently washed two times in 1X PBS and two times in 1X PBS+0.3%
TritonX-100 to permeabilize the cell membranes. Following permeabilization, slides were
incubated with primary antibody diluted in 1X PBS+0.3% TX-100 and 1% BSA overnight
at 4°C. Primary antibody was then washed off with 1X PBS plus 0.3% TritonX-100 and
slides were incubated in secondary antibody diluted in 1X PBS+0.3% TritonX-100 and
1% BSA for 1 hour at room temperature in the dark. Following secondary antibody
incubation, slides were washed with 1X PBS+0.3% TritonX-100, counterstained with
DAPI, and subsequently mounted and visualized with a Leica CTR 6500 microscope.
Cells in culture were washed with 1X PBS and fixed in ice cold 4% PFA for ten minutes.
Following fixation, cells were was two times in 1X PBS and then two times in 1X
PBS+0.3% TritonX-100 to permeabilize cell membranes. Cells were then incubated in
primary antibody diluted in 1X PBS+0.3% TritonX-100 for 1 hour at room temperature.
Primary antibody was washed off with 1X PBS+0.3% TritonX-100, and cells were
subsequently incubated in secondary antibody diluted in 1X PBS+0.3% TritonX-100 for
45 minutes at room temperature in the dark. Following secondary antibody incubation, cells
were washed, counterstained with DAPI, and visualized using a Leica CTR 6500
microscope. Image analysis was performed using Volocity® and ImageJ Software®
(National Institutes of Health, Maryland, USA).
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Figure 2.1 Regions of the mouse brain used for experimental analyses. (A) Image of
the mouse brain with the cortical lobes outlined, along with axes indicating coronal and
sagittal section orientations. (B) Sagittal view of the adult brain at one year of age.
Images were adapted from the Allen Brain Atlas website, available online at www.brainmap.org.

Sagittal
A

Coronal

B
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2.6

Haematoxylin and Eosin Staining

Sagittal cryosections (8uM; Fig. 2.1) were rehydrated in 70% ethanol for 2 minutes and
subsequently stained with CAT Haematoxylin and Eosin Y (H&E; BioCare Medical) for 2
minutes each. Next, slides were dehydrated in increasing ethanol concentrations followed
by xylene washes. Coverslips were then placed onto stained sections using Permount, and
H&E stained and coverslipped cryosections were then viewed and imaged using a Leica
CTR 6500 microscope.

2.7

Neuroprogenitor Cell (NPC) Culture

Pregnant dams were anesthetized and euthanized at embryonic day 13.5 (E13.5) and mouse
embryonic frontal cortices were dissected. At this timepoint, the embryonic cortex is
undergoing a major wave of neurogenesis followed by a period of neuronal differentiation
which terminally differentiates the neuroprogenitors of the brains into cortical neurons
(Slack 1998). Cortical dissection at E13.5 was followed by trituration and plating of cortical
cells onto poly-L-lysine coated 4-well plates. Neuroprogenitor cells were cultured in vitro
in proliferation media – 1% N2 Supplement, 1% penstrep, and 1% glutamax in Neurobasal
media (Gibco®, Life Technologies Inc.) – for two days. After two days in vitro (DIV),
proliferation media was removed and cells were differentiated through the addition of 2%
B-27 Supplement, 1% penstrep, 1% glutamax, and 0.1% bFGF in Neurobasal media
(Gibco®, Life Technologies Inc.) for a further 4 to 8 DIV. In some cases, either 20µM
DMSO or 20µM cPFTα (Sigma) diluted in DMSO was added upon cellular differentiation.
Drugs were administered every 24 hours, and media was changed every 48 hours.

2.8

Adenovirus-Cre Recombinase Infection of Neuroprogenitor Cells

Pregnant dams were anesthetized and euthanized 13.5 days following plug detection
(E13.5), and embryos were removed. Embryonic cortices were dissected, triturated, and
neuroprogenitor cells were cultured in vitro in proliferation media for two days. After two
DIV, cells were infected with an adenovirus expressing either only the Green Fluorescent
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Protein (GFP) (ad-GFP) or expressing the Cre Recombinase gene linked to GFP (adCreGFP) for 1.5 to 2 hours at 37°C.
Following adenovirus infection, cells were differentiated through the addition of
differentiation media for a further 4 to 8 DIV. Differentiation media was changed every 48
hours, and cells were viewed and imaged using a Leica CTR 6500 microscope to look for
correct GFP expression, indicating adenoviral infection.

2.9

Trypan Blue Dye Exclusion Assay

Neuroprogenitor cells in culture were trypsinized for 25 to 30 minutes at 37°C in 1X trypsin
(Gibco) diluted in 1X PBS. Cells were lifted off the plate through mechanical perturbation,
and cell suspensions were placed into 1.5mL Eppendorf tubes and spun in a cold centrifuge
at 1400 RPM for 10 minutes. Cell pellets were then resuspended in 1X PBS and mixed at
a 1:1 ratio with Trypan Blue (Sigma). The number of blue versus white cells was then
counted using a haemocytometer, and percent viability was calculated as follows: %
viability = (# white cells) / (# white + blue cells).

2.10

Database Mining

Data was collected from The Cancer Genome Atlas (TCGA; http://cancergenome.nih.gov/;
n=483)

and

Catalogue

of

Somatic

Mutations

in

Cancer

(COSMIC;

http://cancer.sanger.ac.uk/; n=24) databases for tumour samples across the glioma
spectrum. Expression levels and copy number variation (CNV) for ATRX was examined
and compared to the expression of other tumour suppressor genes, like TP53, or oncogenes,
like IDH. ATRX expression and CNV was also compared to survival time and age of
diagnosis of patients, as well as to tumor grade. Statistical analysis was performed using
GraphPad Prism® software (GraphPad Software, Inc., California, USA).
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CHAPTER 3 – In Vitro Modelling of Gliomagenesis

3.1

Sequential inactivation of Atrx and Tp53 in cultured NPCs

Previous studies identified a significant overlap between mutations in ATRX and TP53 in
glioblastoma multiforme patients (Schwartzentruber 2012; Liu 2012; Kannan 2013). We
know from work in our lab that the loss of Atrx in primary mouse NPCs is detrimental to
cellular viability, genomic stability, and telomeric maintenance (Bérubé 2005; Watson
2013). Furthermore, combined loss of Atrx and Tp53 in vivo is associated with a further
increase in genomic instability, along with a rescue in cell death in cortical neurons at an
embryonic timepoint (Seah 2008). Thus, combinatorial loss of Atrx and Tp53 promotes
NPC survival in vivo, and I propose that loss of both ATRX and TP53 protein expression
may lead to the onset of tumorigenic phenotypes. To test this in vitro, we set up a cell
culture system with sequential loss of ATRX and TP53 function in primary NPCs.
To examine the effects of ATRX and TP53 deficiency in mouse NPCs grown in vitro,
primary cultures were established from Atrx-null (Atrxf/y FoxG1-Cre+) and control (Atrxwt/y
FoxG1-Cre+) embryonic cortices. After two days in vitro (DIV), the cells were
differentiated and treated with either 20µM cyclic Pifithrin-α (cPFTα), a reversible
inhibitor of the transcriptional activation activities of TP53 (Zuco 2008), or with DMSO
alone as a control, for four DIV. To confirm the genotyping results, I performed western
blot analysis of protein extracts obtained from cultured Atrx-null and Cre+ control NPCs
treated with either DMSO or with 20µM cPFTα (Fig. 3.1). Control cells, despite carrying
the FoxG1-Cre recombinase gene, do not harbour the floxed Atrx allele, and thus express
wildtype levels of ATRX protein. This result was validated for control cells treated with
either DMSO alone or 20µM cPFTα diluted in DMSO (Fig. 3.1). NPCs obtained from Atrxnull (Atrxf/y FoxG1-Cre+) embryos show a loss of the ATRX protein, indicating excellent
dissection specificity. Again, this result was seen in Atrx-null cells treated both with DMSO
or cPFTα (Fig. 3.1). As expected, levels of TP53 protein expression remained constant
across both the control and Atrx-null cultured NPCs treated with either DMSO or cPFTα
(Fig. 3.1). These results validate the ability of FoxG1-Cre recombinase in deleting the
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Figure 3.1. Immunoblot validation of ATRX and TP53 protein expression levels in
DMSO- and cPFTα-treated neuroprogenitor cells in culture. Control and Atrx-null
neuroprogenitor cells were grown in vitro and treated with either DMSO alone or with
20µM cPFTα. Protein extracts were taken from cells in culture after six DIV, and the
expression levels of ATRX and TP53 were assessed.

Cre+ Ctrl
Atrx-null
DMSO cPFTα DMSO cPFTα

ATRX

280 kDa

TP53

53 kDa

Incenp

106 kDa

43

floxed Atrx allele in our cell model while not affecting expression levels of TP53. As well,
these results indicate the sensitivity and specificity of the Cre/loxP system in recombining
and silencing specific gene targets in cultured mouse NPCs.

3.2

Characterization of sequential Atrx and Tp53 inactivation in mouse NPCs

Loss of ATRX in NPCs is associated with genomic insult, indicated by an increased number
of cells with γH2A.X foci, some of which overlap with telomeres (Watson 2013). We
further demonstrated that this genomic instability is exacerbated upon the combinatorial
loss of Atrx and Tp53 in vivo (Watson 2013). I therefore wanted to establish whether this
occurs in vitro. Control NPCs grown for six DIV and treated with either DMSO or cPFTα
exhibit a basal level of genomic instability indicated by low levels of immunostaining for
the histone variant γH2A.X, which marks sites of DNA damage, measured on the sixth
DIV. Atrx-null mouse NPCs treated with DMSO alone show amplified DNA damage
qualitatively (Fig. 3.2), as demonstrated by an increase in γH2A.X foci. As well, the relative
number of γH2A.X stained pixels in the images were quantified using ImageJ Software ®,
and an increase in the relative mean gray value compared to control NPCs was seen (Fig.
3.2). Administration of 20µM cPFTα to Atrx-null NPCs in culture lead to a further, albeit
slight, quantitative increase in γH2A.X immunostaining (Fig. 3.2), suggestive of an
increased number of surviving cells despite enhanced DNA damage upon the loss of both
ATRX and TP53 function in mouse NPCs in vitro.
I next examined the effect of sequential ATRX and TP53 inactivation on NPC survival in
vitro, using the trypan blue dye exclusion assay. NPCs were grown in culture for 2 DIV
followed by differentiation and treatment with either DMSO alone or cPFTα every 24 hours
for another 4 DIV. Cellular viability was then measured at 6 DIV. Atrx-null mouse NPCs
treated with DMSO alone had reduced cellular viability compared to Cre+ control cells
treated with DMSO (Fig. 3.3). However, Atrx-null mouse NPCs treated with 20µM cPFTα
showed restored cellular viability comparable to Cre+ control cells treated either with
DMSO or cPFTα (Fig. 3.3). These results demonstrate that the loss of ATRX alone in
mouse NPCs in vitro is associated with reduced cellular viability, and that loss of ATRX
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Figure 3.2. Immunofluorescence assessment of DNA damage foci in DMSO- or
cPFTα-treated neuroprogenitor cells. Control (Atrxwt/y FoxG1-Cre+) and Atrx-null
(Atrxf/y FoxG1-Cre+) neuroprogenitor cells were grown in vitro for 6 days and treated
with either DMSO or 20µM cPFTα. (A) Cells were fixed and immunostained for
γH2A.X (green), a histone variant that marks double stranded DNA breaks. Cell nuclei
were counterstained with DAPI (blue), and images were taken at 10X magnification.
Scale bar = 200µm. (B) Quantification of γH2A.X staining density relative to total DAPI
staining intensity. n=3, p<0.05.
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Figure 3.3. Cellular viability in DMSO- and cPFTα-treated neuroprogenitor cells in
vitro. Control and Atrx-null neuroprogenitor cells were grown in culture for 6 days and
treated with either DMSO alone or 20µM cPFTα. Cellular viability was measured after
six DIV using a trypan blue dye exclusion assay. n=4, *p<0.05.
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followed by TP53 inhibition enables these cells to survive despite high levels of genomic
instability.
Thus, loss of ATRX alone in mouse NPCs causes an accumulation of DNA damage and
reduces cellular viability compared to control cells grown in the same conditions. However,
genetic loss of Atrx, paired with inhibition of TP53 through administration of cyclic-PFTα,
is associated with restored levels of cellular viability, explaining the accumulation of NPCs
exhibiting excess DNA damage. These results indicate that inhibition of the transcriptional
activation activities of TP53, in combination with genetic inactivation of Atrx, induces
genomic instability and promotes cellular survival in vitro.

3.3

Simultaneous deletion of Atrx and Tp53 in cultured NPCs

A second in vitro system was developed following the generation of Atrx and Tp53 double
floxed mice in order to provide a more complete and sustained inactivation of both genes.
This second system uses the Cre/loxP system and adenoviral infection to simultaneously
delete Atrx and Tp53 in cultured NPCs in vitro. Atrxf/y Tp53f/f (double floxed) NPCs are
hemizygous for the Atrx floxed allele and homozygous for the Tp53 floxed allele. Atrxfloxed (Atrxf/y Tp53wt/wt), Tp53-floxed (Atrxwt/y Tp53f/f), and wildtype (Atrxwt/y Tp53wt/wt)
NPCs were also grown in vitro and used as controls. After two DIV, cultured NPCs were
differentiated and infected with an adenovirus carrying Cre recombinase linked to the
Green fluorescent protein gene (ad-CreGFP), which will recombine and delete sequences
flanked by loxP sites. Infected cells will also fluoresce green because of the expression of
GFP. Through this approach, NPCs lacking ATRX and TP53 proteins (double-null) were
created, along with cells harbouring a loss of only ATRX (ATRX-null) or only TP53
(TP53-null). Wildtype cells infected with ad-CreGFP were used to control for effects of
Cre recombinase expression. Additionally, an adenovirus carrying only the GFP gene and
lacking the Cre recombinase gene (ad-GFP) was used on cultured NPCs to control for any
effects of adenovirus infection.
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Green fluorescence was observed in NPCs of all genotypes infected with either ad-GFP or
ad-CreGFP, indicating that adenovirus infection was successful. Examination of cellular
appearance indicated that adenovirus infection did not affect cell morphology after four
DIV (Fig. 3.4). As NPCs differentiate in vitro, they begin to develop characteristics of
neurons: long finger-like processes reaching out in all directions, large cell bodies, groups
of cells growing in clumps, and cell colonies growing flat (horizontally) along the plate
(Leach 2011). The wildtype, Atrx-floxed, Tp53-floxed, and double floxed cells treated with
ad-GFP demonstrated these characteristics, indicating that adenovirus infection does not
affect cellular morphology at a qualitative level. Additionally, wildtype NPCs infected with
ad-CreGFP also showed these neuronal characteristics, indicating that Cre recombinase
expression does not affect cellular morphology (Fig. 3.4). Thus, adenovirus infection of
NPCs was successful and was not associated with gross cellular morphological alterations.
I next performed western blot analyses to verify deletion of ATRX and TP53 in the
appropriate cells. Immunoblot analysis was performed on cellular extracts obtained from
wildtype (Atrxwt/y Tp53wt/wt), Atrx-floxed (Atrxf/y Tp53wt/wt), and double floxed (Atrxf/y
Tp53f/f) cells in culture infected with either ad-GFP or ad-CreGFP. ATRX and TP53
proteins were present in all genotypes treated with ad-GFP, demonstrating that adenovirus
infection alone does not lead to alterations in ATRX or TP53 protein levels (Fig. 3.5).
Wildtype (Atrxwt/y Tp53wt/wt) NPCs treated with ad-CreGFP also show normal ATRX and
TP53 protein levels. Upon ad-CreGFP infection, Atrx-floxed (Atrxf/y Tp53wt/wt) NPCs show
a reduction of ATRX alone, while double floxed (Atrxf/y Tp53f/f) NPCs show a reduction of
both ATRX and TP53 protein expression (Fig. 3.5). These results validate efficient Cremediated recombination of the Atrx and Tp53 floxed alleles. The substantial decrease in
protein levels upon ad-CreGFP infection relative to ad-GFP infection indicates a high
infection and recombination efficiency in NPCs using this approach.

3.4

Characterization of simultaneous ATRX and TP53 loss in mouse NPCs

Following

successful

validation

of

adenovirus

infection

in

mouse

NPCs,

immunofluorescence staining was performed for the histone variant γH2A.X to assess
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Figure 3.4. Green fluorescence validation of adenovirus infection in ad-GFP and adCreGFP infected neuroprogenitor cells. Wildtype (Atrxwt/y Tp53wt/wt; A, A’), Atrxfloxed (Atrxf/y Tp53wt/wt; B, B’), Tp53-floxed (Atrxwt/y Tp53f/f; C, C’), and double floxed
(Atrxf/y Tp53f/f; D, D’) neuroprogenitor cells were grown in culture for two DIV and
subsequently differentiated and infected with either ad-GFP (A, B, C, D) or ad-CreGFP
(A’, B’, C’, D’). GFP expression (green) was assessed after four DIV to examine
adenovirus infection efficiency. Scale bar=200µm.
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Figure 3.5.

Immunoblot validation of Cre recombinase activity in infected

neuroprogenitor cells. Wildtype (Atrxwt/y Tp53wt/wt), Atrx-floxed (Atrxf/y Tp53wt/wt), and
double floxed (Atrxf/y Tp53f/f) neuroprogenitor cells were grown in vitro for two days
and subsequently infected with either ad-GFP or ad-CreGFP. After six DIV, protein
extracts were taken from cells in culture, and ATRX and TP53 protein levels were
assessed via immunoblotting techniques. INCENP and α-tubulin were assessed as
loading controls.

Atrxf/y Tp53WT/WT

WT
AdGFP

AdCre

AdGFP

AdCre

Atrxf/y Tp53f/f
AdGFP

AdCre

AdGFP

AdCre

ATRX

280 kDa

INCENP

106 kDa

53 kDa

TP53

50 kDa

αTubulin

52

genomic instability upon the simultaneous loss of ATRX and TP53 in NPCs in vitro. AdGFP infected double floxed NPCs in culture are comparable to wildtype cells, as they do
not show loss of ATRX or TP53 protein expression and appear morphologically similar to
controls. Staining for γH2A.X in these cells was minimal, indicative of very little DNA
damage occurring in these double floxed cells treated with ad-GFP (Fig. 3.6). However,
double floxed NPCs treated with ad-CreGFP and immunostained for γH2A.X show an
increase in the number of cells with DNA damage foci, indicative of the induction of
excessive genomic instability in these cells upon loss of ATRX and TP53 expression (Fig.
3.6). Similar to the results seen in the previous in vitro system outlined in section 3.1, the
simultaneous loss of ATRX and TP53 in NPCs grown in culture leads to a much more
robust and significant increase in genomic insult.
Cellular viability was measured in wildtype (Atrxwt/y Tp53wt/wt), Atrx-floxed (Atrxf/y
Tp53wt/wt), and double floxed (Atrxf/y Tp53f/f) NPCs infected with either ad-GFP or adCreGFP using the trypan blue dye exclusion assay. All genotypes infected with ad-GFP
alone showed high levels of cellular viability (Fig. 3.7), demonstrating that adenovirus
infection does not have disruptive effects on cell survival. Additionally, wildtype cells
treated with ad-CreGFP showed no reduction in cellular viability, indicating that Cre
recombinase expression in NPCs does not have negative effects on cellular survival relative
to ad-GFP infected controls (Fig. 3.7). However, Atrx-floxed NPCs treated with adCreGFP show reduced cellular viability, consistent with previous results showing
decreased cellular survival in Atrx-null NPCs. Simultaneous loss of ATRX and TP53 via
ad-CreGFP infection of double floxed NPCs results in restored cellular viability,
comparable to ad-GFP infected and wildtype controls (Fig. 3.7). These results indicate that
the additional loss of TP53 allows ATRX-null NPCs to survive despite the massive
induction of genomic instability in these cells.

3.5

Summary of Results

To summarize, research is identifying large cohorts of glioma patients harbouring
mutations in both ATRX and TP53. We know that ATRX loss alone does not induce
53
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Figure 3.6. Immunofluorescence assessment of DNA damage in ad-GFP and adCreGFP infected neuroprogenitor cells in vitro. Double floxed (Atrxf/y Tp53f/f)
neuroprogenitor cells were grown in culture for two days and subsequently infected with
either ad-GFP or ad-CreGFP. After six DIV, cells were fixed and immunostained for
γH2A.X (red) to assess DNA damage. GFP expression (green) indicates cells that have
been successfully infected with the adenovirus. Scale bar=200µm.
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Figure 3.7. Cellular viability of ad-GFP and ad-CreGFP infected neuroprogenitor
cells in vitro. Wildtype (Atrxwt/y Tp53wt/wt), Atrx-floxed (Atrxf/y Tp53wt/wt), and double
floxed (Atrxf/y Tp53f/f) cells were grown in culture for two days and subsequently
differentiated and infected with either ad-GFP or ad-CreGFP. After six DIV, cellular
viability was assessed using a trypan blue dye exclusion assay. n=3, *p<0.05.
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Double floxed

carcinogenesis; in fact, ATRX loss is associated with the stabilization of TP53 and
activation of its downstream apoptotic pathways (Seah 2008; Watson 2013). Examination
of Atrx and Tp53 inactivation in cultured NPCs, both sequentially and simultaneously,
identified increased genomic insult and restored cellular viability in both systems. These
phenotypes are common characteristics of tumorigenic cells and may provide a model of
early events in gliomagenesis. Furthermore, these results may afford insight into the
molecular mechanisms of subpopulations of glioma that carry a loss of both ATRX and
TP53 expression in vivo.
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CHAPTER 4 – In Vivo Modelling of Gliomagenesis

4.1

Database Mining to Investigate Known ATRX Loss-of-Function Mutations

ATRX mutations have been identified in different types of cancers, and several web
databases have begun cataloguing ATRX mutations, expression levels, and copy number
variation across the cancer spectrum. The Cancer Genome Atlas (TCGA), curated by the
National Institutes of Health (NIH) and the National Institute of Cancer (NIC) run by the
U.S. Department of Health and Human Services, has catalogued relative expression levels
for a wide array of genes across several hundred glioblastoma multiforme tissue samples.
Using these data, expression levels for the ATRX gene was compared between all of the
GBM patient samples, and tumours harbouring overexpression, normal, or underexpression
of ATRX were catalogued.
Of the 483 total GBM patient samples available on TCGA, the majority of these tumours
harboured wildtype expression levels for ATRX, according to log2 expression cutoff values
generated from past literature that used expression level data from TCGA (Cancer Genome
Atlas Research Network, 2008). There were, however, several patient samples that did
harbour either low (n=27) or high (n=13) expression of ATRX, and when correlated with
patient survival, tumours harbouring lower expression of ATRX demonstrate better overall
survival (p=0.065; Fig. 4.1a). As well, patient tumour samples with low ATRX expression
demonstrated a significantly earlier age of diagnosis compared to tumour samples with
normal or high expression of ATRX (Fig. 4.1b). These results are consistent with a previous
report that identified an earlier age of diagnosis as well as better overall patient survival for
patient with ATRX-null pancreatic neuroendocrine tumours (Jiao 2011). Thus, although
detrimental to genome stability and normal mitosis, ATRX mutations may represent a subset
of GBM tumours that demonstrates an earlier age of diagnosis as well as a better overall
patient survival compared to tumours with normal or high expression of ATRX.
Data from the Catalogue of Somatic Mutations in Cancer (COSMIC) database include copy
number variation status and mutation analysis for ATRX for established glioma cell lines.
Several mutations in ATRX were identified, spanning across the entire ATRX gene,
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Figure 4.1. Mining of The Cancer Genome Atlas database for glioblastoma
multiforme tumour patients. (A) ATRX expression correlated with patient age of
diagnosis. *p<0.05, n=483 tumour samples. (B) Expression of ATRX in GBM patients
was correlated with patient time to death. p=0.065, n=483 tumour samples.
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demonstrating the non-specificity and wide variety of ATRX mutations that are relevant to
glioma development (Fig. 4.2). Additionally, the number of segments as well as abnormal
segments throughout the genome of each glioma cell line could be counted from the copy
number variation data on the COSMIC database (Fig. 4.3a,b), which can be used as a
marker for genomic instability in these tumours. Cell lines created from female patients
were not used in the analysis because of the lack of expression data for ATRX. Since female
cells undergo random X-chromosome inactivation, there would be no way to know whether
these cells had gained or lost the active or inactive copy of the ATRX locus. Given that only
male samples were used, the total number of tumour samples included in the analysis was
low (n=24).
Interestingly, none of the included male glioma cell lines harboured a loss of the ATRX
gene locus; however, there were a number of samples that carried a gain (2 or 3+ copies;
n=15 and 4, respectively) of the ATRX locus. ATRX copy number was correlated with the
total number of segments across the genome, the number of abnormal segments, as well as
the number of whole chromosome gain/loss events (Fig. 4.3), and even the gain of ATRX
genomic loci may be detrimental to both genomic stability and normal chromosome
segregation. Samples with added copies of the ATRX locus showed significant increases in
the number of segments as well as the number of abnormal segments, indicative of
enhanced genomic instability. As well, additional ATRX copies also correlated with an
increase in whole chromosome gain or loss events (Fig. 4.3c), indicative of chromosome
misseggregation events during mitosis. These results indicate a dose-dependence for ATRX,
demonstrating that both loss of ATRX expression or gain of the ATRX locus is associated
with genomic instability and chromosome misseggregation.

4.2

Using In Vivo Model Systems to Gain Insights into Gliomagenesis

The findings outlined in Chapter 3 of this thesis suggest that the combined inactivation of
ATRX and TP53 promotes NPC survival in the presence of genomic instability, which is a
hallmark of cancer. In this chapter, we explored the possibility that loss of ATRX alone, or
in combination with TP53 loss, could be conducive to gliomagenesis.
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Figure 4.2 Mutation distribution for ATRX within catalogued glioma samples. Data
from

the

Catalogue

of

Somatic

Mutation

in

Cancer

(COSMIC;

http://cancer.sanger.ac.uk/) database was analyzed and ATRX mutation distribution
within glioma samples was organized. Colours within the pie chart correspond to the
colours described in the table below, and mutation types are listed in order of frequency.

Colour

Mutation Type

Percentage

Deletion Frameshift

32.62

Substitution Nonsense

28.88

Substitution Missense

20.86

Insertion Frameshift

7.49

Substitution Synonymous

2.67

Deletion In-frame

0.53

Complex

0.53
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Figure 4.3. Mining of the Catalogue of Somatic Mutations in Cancer (COSMIC)
database examining established glioma cell lines. The total number of segments
within the genome (A), the number of abnormal segments (B), and the number of whole
chromosome gains/losses (C) were counted in glioma cell lines originating from male
tumour patients. Glioma cell lines with normal ATRX copy number (one copy, red) were
compared with those cell lines harbouring two copies (purple) or three copies (blue) of
the ATRX gene locus. n=24, *p<0.05
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4.2.1

Transcriptional Profiling of the Atrx-null Neonatal Mouse Forebrain

To determine the transcriptional effects of Atrx loss alone in the mouse forebrain, a
microarray was performed on control and Atrx-null mouse forebrains at birth (P0.5) (Levy
2008). Mice carrying the Atrx gene harbouring loxP sites surrounding exon 18 were mated
to mice carrying the Cre recombinase gene under the control of the FoxG1 promoter to
inactivate the Atrx gene specifically in the mouse forebrain beginning at embryonic day 8.5
(E8.5) (Bérubé 2005). FoxG1-Cre+ Atrxwt/y control mice were used to compare expression
levels of genes across the genome upon the loss of ATRX in the neonatal mouse forebrain.
In total, 861 genes were significantly upregulated on the microarray by 1.3-fold or more in
the Atrx-null neonatal mouse forebrain, and many of these genes are involved in the
development of glioma based on previous literature. Gene ontology (GO) term analysis of
the top 100 increased targets in the Atrx-null neonatal mouse forebrain identified commonly
upregulated pathways, a number of which are related to cancer development (Table 4.1).
For example, genes involved in the WNT pathway were most significantly upregulated
(including Wnt7b, Wnt5a, and Fzd7), while pathways involved in stem cell characteristics
(Role of NANOG in Embryonic Stem Cell Pluripotency and Human Embryonic Stem Cell
Pluripotency) and angiogenesis (Factors Promoting Cardiogenesis in Vertebrates) were
also significantly upregulated. These results suggest that the loss of Atrx expression
embryonically in the mouse forebrain is associated with the upregulation of a number of
signaling pathways involved in cancer development in the differentiated and surviving cells
of the neonatal mouse frontal cortex.
Further literature searches identified that several upregulated targets from the microarray
are involved in the regulation of cellular processes important to gliomagenesis. For
example, genes involved in migration/invasion (Cxcl2, Mmp2, Mmp14, Igfbp2, Gsn, Lox,
Mdk, and ErbB3), epithelial-to-mesenchymal transition (EMT; FoxC1, FoxC2, S100A11,
and Ahnak), and the WNT pathway (Wnt5a, Wnt7b, and Fzd7) were significantly
upregulated on the microarray and have an established role in glioma development
(Kamino 2011; Li 2013; Chen 2013A; Rahme 2014; Ulasov 2014; Han 2014A; Han 2014B;
Luo 2014). These glioma-related genes were validated using quantitative real time
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Table 4.1 GO term analysis of upregulated targets from the Atrx-null and control P0.5
microarray.

Canonical Pathways

p-value

Molecules

1

Wnt/β-catenin
Signaling

4.72E+00

FZD8,SFRP2,CDH5,WNT7B,TGFBR3,TL
E4,SFRP1,PPP2R1B,SOX5,FZD7,WNT5A

2

Basal Cell Carcinoma
Signaling

4.34E+00

FZD8,WNT7B,BMP7,BMP6,BMP5,FZD7,
WNT5A

3

Factors Promoting
Cardiogenesis in
Vertebrates

3.69E+00

FZD8,TGFBR3,BMP7,BMP6,BMP5,PRKD
1,FZD7

4

Role of NANOG in
Mammalian Embryonic
Stem Cell Pluripotency

3.11E+00

FZD8,WNT7B,BMP7,BMP6,BMP5,FZD7,
WNT5A

5

Role of Osteoblasts,
Osteoclasts and
Chondrocytes in
Rheumatoid Arthritis

3.08E+00

FZD8,SFRP2,MMP14,WNT7B,BMP7,SFR
P1,BMP6,BMP5,FZD7,WNT5A

6

Human Embryonic
Stem Cell Pluripotency

2.73E+00

FZD8,WNT7B,BMP7,BMP6,BMP5,FZD7,
WNT5A

7

Aryl Hydrocarbon
Receptor Signaling

2.62E+00

TGM2,GSTM1,GSTM2,NFIA,ALDH1A2,
CDKN1A,NFIB

8

Complement System

2.30E+00

SERPING1,C1QC,CFH

9

Role of Wnt/GSK-3β
Signaling in the
Pathogenesis of
Influenza

1.95E+00

FZD8,WNT7B,FZD7,WNT5A

10

Leukocyte
Extravasation Signaling

1.95E+00

CDH5,CLDN1,CXCL12 (includes
EG:20315),
MMP14,MMP2,CLDN2,PRKD1
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polymerase chain reaction (qRT-PCR) showing significantly increased mRNA expression
levels in the ATRX-null mouse forebrain at birth (Fig. 4.4).
Due to the infiltrative and aggressive nature of gliomas, misregulation of cellular processes
like migration/invasion and EMT could initiate the development and progression of glioma.
ErbB3 – a member of the epidermal growth factor receptor (EGFR) family – was the most
upregulated target by qRT-PCR, and increased expression of this gene was validated further
using both in situ hybridization (ISH) and immunoblotting of control and Atrx-null
forebrain cryosections (Fig. 4.5). Qualitative analysis of ErbB3 ISH performed on control
and Atrx-null cryosections demonstrated a consistent upregulation of ErbB3 mRNA (Fig.
4.5a). Western blots were then performed to examine whether ERBB3 and phosphorylatedERBB3 protein levels were altered in the Atrx-null mouse forebrain at birth. Three out of
four control and Atrx-null forebrain pairs demonstrated an increase in the protein
expression of the 100kDa isoform of both ERBB3 and p-ERBB3 (Fig. 4.5b). The ERBB3
protein is known to lie at the top of a signalling cascade involved in promoting cell growth,
migration, protein synthesis, and invasion (Kim 1998; Kamalati 2000; Jones 2006).
Activated p-ERBB3 signals through the AKT pathway, and phosphorylated-AKT was also
upregulated in the same three control/Atrx-null pairs. One pair that showed very low levels
of ATRX protein, however, did not demonstrate increased expression of ERBB3, and thus
downstream molecules like p-AKT also lacked increased expression in this pair. Therefore,
ATRX loss is associated with the upregulation of several gene targets related to glioma
development. We propose that Atrx loss may create a cellular environment conducive to
tumorigenesis through the direct or indirect upregulation of gene targets known to be
associated with cellular phenotypes common to glioma development, including the
upregulation of ERBB3 and p-ERBB3 in some cases.

4.2.2

In Vivo Model of ATRX and TP53 Inactivation

As Atrx-null male mice have been shown in the literature to die postnatally around P17-21
or earlier (Bérubé 2005), using these mice for a long-term tumour study was not feasible.
Therefore, female Atrx mosaic mice were used, as these mice do survive long-term and
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Figure 4.4 Validation of P0.5 microarray target genes using quantitative real time
PCR. RNA was extracted from neonatal mouse control (Atrxwt/y FoxG1-Cre+) and Atrxnull (cKO; Atrxf/y FoxG1-Cre+) forebrains, and qRT-PCR was performed to examine the
expression status of target genes shown to be overexpressed on the P0.5 microarray.
Target genes known to be involved in glioma development were examined, and these
genes are involved in the regulation of such cellular processes as migration/invasion (A),
epithelial-to-mesenchymal transition (B), and the WNT pathway (C). n=6-8, *p<0.05
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Figure 4.5 Validation of increased ErbB3 mRNA and ERBB3 protein levels in the
Atrx-null neonatal mouse forebrain. In situ hybridization (ISH; A) was performed on
8µm thick coronal cryosections from Atrx-null (cKO) and control neonatal mouse
forebrains using a DIG-labeled ErbB3 mRNA probe, Immunoblotting (B) was
completed on protein extracts from the P0.5 forebrains of four control and Atrx-null
pairs. Scale bars= 200µm.
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have a life expectancy similar to that of controls (Bérubé 2005). These female mice have
one wildtype Atrx allele and one Atrx-floxed allele, and were mated with a mouse line
harbouring the Cre recombinase gene under the control of the Nestin promoter (Atrxf/wt
Nes-Cre+). The Nestin promoter directs expression of Cre recombinase throughout the
entire mouse CNS beginning at embryonic day 11.5 (Tronche 1999). However, because of
random X-chromosome inactivation, female mice heterozygous for the floxed Atrx allele
will show complete inactivation of Atrx in 50% of cells in the brain, while the other 50%
will retain wildtype Atrx levels. This, therefore, creates a mosaic pattern of Atrx-expressing
and Atrx-non-expressing cells in the CNS. Mice harbouring the floxed Atrx allele but
negative for the Nes-Cre recombinase gene (Atrxf/wt Nes-Cre-) were used as controls.
Mice with mosaic expression of ATRX in the brain (Atrxf/wt Nes-Cre+) were then crossed
to a mouse line heterozygous for the Tp53 gene (Jacks 1994). Consequently, these mice
harbour a compete loss of one Tp53 allele in every cell of the body, and this expression is
not affected by the presence of the Cre recombinase gene. Together, experimental (double
heterozygous) mice contain one floxed Atrx allele along with the presence of the Nes-Cre
gene, and they also harbour a deletion of one Tp53 allele beginning from conception
(Atrxf/wt Nes-Cre+ Tp53+/-). Mice heterozygous for Atrx or Tp53 alone were used to control
for the effects of each gene (Atrxf/wt Nes-Cre+ Tp53+/+ or Atrxf/wt Nes-Cre- Tp53+/-,
respectively), along with fully wildtype mice as a negative control (Atrxf/wt Nes-CreTp53+/+).
Weight measurements were taken weekly for each genotype and averaged between each
cohort (Fig. 4.6a). Both wildtype and Tp53 heterozygous mice demonstrated a typical
growth pattern, and the weights of these two cohorts were not significantly different from
one another. Additionally, both the double heterozygous and Atrx heterozygous mice
shared a similar growth pattern, and the weights of these two cohorts were also not
significantly different from one another. However, the double heterozygous and Atrx
heterozygous mice demonstrated reduced average weights compared to the wildtype and
Tp53 heterozygous mice, and many of the timepoints showed a significant difference
between these two groups of mice. This shows that mice lacking the Atrx gene in half of
their brain cells starting from E11.5 exhibit reduced postnatal growth over time, while
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Figure 4.6. Effect of Atrx and Tp53 heterozygosity on mouse weight and survival over
time. (A) Wildtype (black, n=8), Tp53 heterozygous (blue, n=9), Atrx heterozygous
(green, n=10), and double heterozygous (red, n=9) mice were weighed weekly from 10
weeks of age. Weights for each cohort were averaged and tracked over time. (B)
Survival of wildtype (black, n=8), Tp53 heterozygous (blue, n=9), Atrx heterozygous
(green, n=10), and double heterozygous (red, n=9) mice was noted and cohort’s survival
was compared using a Mantel-Cox curve comparison test. *p<0.05
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heterozygosity of Tp53 does not affect overall growth. Combined heterozygosity of the
Atrx and Tp53 genes does not appear to affect the growth of these mice in a positive or
negative way compared to the Atrx heterozygous mice alone (Fig. 4.6a).
Mouse growth and behaviour was examined throughout their lifetime, and mice were
euthanized at endpoints deemed suitable according to the Canadian Council for Animal
Care. For example, excessive lesions affecting the comfort level of the mouse or changes
in the mouse’s gait affecting its ability to feed properly would be deemed as appropriate
endpoints for the mouse. The overall survival curves on each cohort was tracked, and
survival was compared between genotypes (Fig. 4.6b). With the exception of a few outliers,
the wildtype and Atrx heterozygous mice survived at a similar rate, with the majority
surviving past 600 days. Additionally, the double heterozygous and Tp53 heterozygous
mice showed similar survival curves, with the majority or entirety of the cohort dying by
around 600 days and a mean survival for both cohorts of around 500 days. Taken together
the results show that heterozygosity of the Tp53 gene (but not Atrx) leads to reduced
lifespan in these mice. Combined Atrx and Tp53 heterozygosity did not influence the
survival of these mice in a positive or negative way compared to the Tp53 heterozygous
mice alone (Fig. 4.6b).
Prior to euthanasia, mice were perfused with 4% paraformaldehyde (PFA) and images were
taken of the internal organs of each mouse to determine whether the onset of death was due
to the presence of internal tumours or lesions, which are known to develop in Tp53
heterozygous mice (Table 4.2). As expected, the majority of wildtype and Atrx
heterozygous mice showed few or no internal lesions, lacked enlarged organs like the
spleen and liver, and maintained normal internal organ function throughout their lifetime.
However, both the Tp53 heterozygous and Atrx/Tp53 double heterozygous cohorts showed
a large amount of internal dysfunction, including one or more of the following: intestinal,
renal, thymic and hepatic lesions, enlarged spleens and livers, distended abdomens, and
odd gaits (Table 4.2).
These results validate the likelihood that the internal lesions and abnormalities in the Tp53
heterozygous and Atrx/Tp53 double heterozygous mice were the cause of death, rather than
any severe neurological phenotypes. However, there is a possibility of the combined
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Table 4.2 Outline of internal abnormalities in Atrx and Tp53 heterozygous mice.

Genotype
Double Het
Double Het
Double Het
Double Het
Double Het
Double Het

DOB
(m/d/y)
08/28/12
10/24/12
10/24/12
11/16/12
12/06/12
12/06/12

Liver
None
None
None
None
None
None

Kidneys
None
None
None
None
Yes
Yes

Double Het
Double Het
Double Het
Atrx Het
Atrx Het
Atrx Het
Atrx Het
Atrx Het

12/09/12
12/09/12
12/09/12
08/28/12
09/05/12
10/01/12
10/01/12
10/01/12

None
None
None
Yes
None
None
None
None

None
None
None
Yes
None
None
None
None

Atrx Het
Atrx Het
Atrx Het
Atrx Het
Tp53 Het
Tp53 Het
Tp53 Het
Tp53 Het
Tp53 Het
Tp53 Het

12/27/12
12/27/12
01/01/13
01/01/13
08/28/12
08/28/12
09/05/12
09/05/12
11/16/12
12/06/12

None
None
None
None
None
Yes
None
None
None
Yes

Tp53 Het
Tp53 Het
Tp53 Het
Wildtype
Wildtype
Wildtype
Wildtype
Wildtype
Wildtype
Wildtype
Wildtype

12/27/12
12/27/12
01/01/13
08/28/12
09/12/12
10/01/12
11/16/12
11/16/12
12/06/12
01/01/13
01/01/13

None
None
None
None
None
None
None
None
None
None
None

Internal Lesions/Abnormalities
Intestines
Spleen
Thymus
None
None
Yes
None
None
None
None
None
Yes
Yes
None
None
Yes
None
None
None
None
None

Limbs
Yes
Yes
None
None
None
None

Enlarged
None
None
Enlarged
None
None
None
None

None
Yes
None
None
None
None
None
None

None
None
None
None
None
None
None
None

None
None
None
None
None
Yes
Yes
None
Yes
Yes

Yes
None
None
None
None
None
Yes
Fluidfilled
None
None
None
None
None
Yes
Yes
None
Yes
Yes

None
None
None
None
None
None
None
Enlarged
Enlarged
Enlarged

None
None
None
None
None
None
None
None
None
None

None
None
None
None
Yes
None
None
None
None
None

None
None
None
None
None
None
None
None
None
None
None

None
None
Yes
None
None
None
None
None
None
None
None

None
Enlarged
Enlarged
None
None
None
None
None
None
None
None

None
Yes
None
None
None
None
None
None
None
None
None

None
None
None
None
None
None
None
None
None
None
None
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Other
None
None
None
None
None
Growth on
spine
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
Distended
abdomen
None
None
None
None
None
None
None
None
None
None
None

heterozygosity of Atrx and Tp53 in the brain leading to abnormal proliferation, potentially
due to enhanced genomic instability in these cells as was seen in the in vitro systems
developed and discussed in chapter 3. Brain sagittal cryosectioning and H&E staining is
underway in order to investigate the brain histology of these mice cohorts and determine
whether combined ATRX and TP53 loss leads to dysplasia or tumours. This in vivo model
represents a tool that can be used in future studies to determine the interplay between Atrx
and Tp53 mutations in the development of glioma.
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CHAPTER 5 – Discussion and Conclusions

5.1

Summary of Thesis Findings

The main objective of the experiments conducted in this thesis was to establish whether the
loss of Atrx in combination with the loss of TP53 function, both in vitro and in vivo, could
lead to genetic and molecular changes capable of transforming normal neurons in the
central nervous system (CNS) into tumorigenic cells. To test this in vitro, two model
systems were set up using primary mouse neuroprogenitor cell (NPC) cultures. These NPCs
lacked either Atrx alone or lacked both Atrx and TP53 function. The first in vitro system
harboured the genetic loss of the floxed Atrx allele embryonically, followed by the
inhibition of TP53 using a reversible inhibitor drug called cyclic Pifithrin-α (cPFTα) in
culture. The findings from these experiments showed that the loss of Atrx alone in mouse
NPCs reduced cellular viability significantly in vitro after six days of culturing, as
described previously (Bérubé 2005). However, Atrx-null cells treated with 20µM cPFTα to
inhibit TP53 function demonstrated restored cellular viability, similar to viability levels of
control cells treated with either DMSO or cPFTα. Despite restored cellular viability, Atrxnull cells treated with cPFTα demonstrated increased DNA damage, as shown by increased
γH2A.X immunostaining. Atrx-null cells grown in culture treated with DMSO also showed
increased genomic instability; however, this instability was trending towards a further
increase when both ATRX and TP53 functions were ablated. Thus, despite further genomic
insult upon the sequential loss of function of both ATRX and TP53 in vitro, these
ATRX/TP53 double-null cells exhibited restored cellular survival – a phenotype commonly
noted in tumorigenic cells.
A second in vitro system was created that examined a more robust and simultaneous genetic
inactivation of both Atrx and Tp53 in culture. This system used Atrx and Tp53 double floxed
mouse NPCs grown in culture, and infected with an adenovirus harbouring the Cre
recombinase gene linked to the Green fluorescence protein (Gfp) gene, along with
appropriate controls. Expression of Cre recombinase enabled the genetic silencing of either
Atrx alone, Tp53 alone, or both Atrx and Tp53 simultaneously. NPCs lacking only ATRX
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expression showed reduced cellular viability compared to control cells. However, NPCs
lacking both ATRX and TP53 expression had cellular viability comparable with controls
and excessive genomic instability. This second in vitro system reiterates the abnormal
cellular phenotypes shown in the first system; however, it appears that this second system
may be more robust and reproducible likely because of the specificity of the adenovirus
Cre recombinase infection versus the addition of a reversible TP53 inhibitor drug.
Examination of available data from online databases allowed us to identify patient tumor
samples that harboured low, normal, and high gene expression levels of ATRX, as well as
to assess copy number variation (CNV) at the ATRX locus. Examination of ATRX gene
expression indicated that glioblastoma multiforme tumours harbouring low ATRX
expression had a significantly earlier age of diagnosis, along with a trend towards longer
overall survival, compared to those patients that had tumours carrying normal or even high
expression levels for ATRX. As well, CNV analysis at the ATRX locus indicated that glioma
tumour cell lines carrying an excess number of copies of ATRX had a significant increase
in genomic instability – as signified by an increase in the total number and the number of
abnormal segments. In addition, glioma cell lines carrying higher copy numbers for the
ATRX locus also showed a trend towards more whole chromosome gains or losses,
indicative of chromosomal congression and separation defects during mitosis.
Experiments conducted in vivo examined the effects of Atrx loss, both alone and in
combination with Tp53, in the mouse CNS. Analysis of a microarray performed at birth
(P0.5) on control and Atrx-null mouse forebrains indicated a significant increase in the
expression of a number of genes known to be associated with glioma development and
progression in the Atrx-null neonatal mouse forebrain. A number of these genes were
validated by qRT-PCR based on their relevance to glioma, and were shown to be
significantly upregulated in the P0.5 Atrx-null mouse forebrain compared to Cre-positive
controls. Increased expression of the ErbB3 gene was further validated using in situ
hybridization (ISH) and immunoblotting techniques, as it is a member of the epidermal
growth factor receptor (EGFR) family of proteins and signals through the AKT and MAPK
pathways. Western blots indicated an increase in ERBB3 and phospho-ERBB3 proteins, as

78

well as phospho-AKT – a signalling molecule downstream of ERBB3 – showed an increase
in the majority of Atrx -null mouse forebrains at P0.5.
Examination of Atrx and Tp53 loss in vivo showed that mosaic expression of Atrx in the
mouse brain leads to reduced postnatal growth of the mice, while Tp53 heterozygosity
caused tumours and abnormalities of several organs and reduced survival.

5.2

In vitro NPC Culture Systems as a Model of Glioma Development

Tumours within the glioma spectrum are highly heterogeneous, and the cell of origin for
gliomas is a greatly disputed topic among scientists (Furnari 2007). Additionally, the
underlying genetic and molecular alterations leading to glioma formation are vast and not
well understood (Furnari 2007). Because of this complexity, the creation of systems to
model the development of glioma has been extremely difficult. The present study describes
two in vitro NPC culture systems that may be useful in modelling the initial steps of
gliomagenesis.
Several studies have identified a significant overlap between mutations in ATRX, or loss of
ATRX protein expression, and mutations in TP53 (Schwartzentruber 2012; Liu 2012;
Kannan 2013; Wu 2014). However, whether mutations in ATRX occur first and act to drive
tumorigenesis, or are a result of other prior mutations, is unknown. Thus, the development
of in vitro model systems allowing for different temporal inactivation of both TP53 and
ATRX function in mouse NPCs was important to identify whether sequential or
simultaneous loss of ATRX and TP53 function would better drive tumorigenic
characteristics.
Mouse NPCs were used for both in vitro culture systems described in the present study.
While the cell of origin for gliomas is still hotly debated within this field, recent evidence
is pointing towards NPCs, or neural stem cells (NSCs), as potential targets. Several studies
have now identified glioblastoma stem cells, or initiating cells (GICs), as playing a major
role in tumor development, tumour maintenance, and therapeutic resistance (Salmaggi
2006; Johannessen 2009; Kroonen 2011). Furthermore, these GICs demonstrate many
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properties akin to NSCs (Stiles 2008), creating the link between NSCs and glioma tumour
formation. Finally, the adult brain harbours several NSC niches that retain the ability to
produce neurons and glia throughout life, thus providing a source of progenitor cells in
adults that could become oncogenic following mutagenesis (Luskin 1993; Lois 1994). This
evidence justifies the use of NPCs in vitro as a model system for glioma development, and
was the reason behind using this cell type for both the sequential and simultaneous in vitro
systems described in the present study.

5.2.1

Sequential Loss of ATRX and TP53 Function in Mouse NPCs

The first in vitro model system took advantage of the FoxG1-Cre+ Atrxf/y mouse NPC
culturing system set up on our lab. Atrx-null NPCs in culture undergo massive TP53mediated cell death at 6-7DIV (Bérubé 2005; Seah 2008; Watson 2013). To combat cell
death in vitro, the reversible inhibitor of TP53 called cyclic Pifithrin-α (cPFTα) was added
to the culture media after two days in vitro. Therefore, following genetic loss of Atrx at
E8.5, TP53 protein function was ablated using cPFTα approximately 7 days later in culture.
Trypan blue viability assays indicated that cellular survival in these Atrx-null/cPFTαtreated NPCs was restored to control levels.
Previous studies have shown that Atrx loss in cortical neurons during embryogenesis leads
to an increase in replication-associated DNA damage foci, and this genomic instability is
further enhanced upon the combined loss of ATRX and TP53 embryonically in vivo
(Watson 2013). In the present study, genomic instability is shown to be significantly
increased upon the loss of Atrx in NPCs, and this DNA damage is increased further upon
the treatment of Atrx-null cells with cPFTα. Qualitatively, this enhancement of genomic
instability can be easily seen; however, quantifying immunofluorescence signals in
growing NPCs is a difficult task. This is because NPCs tend to grow in clumps and in small
colonies, rather than creating a confluent cell monolayer across the culture plate (Leach
2011). Therefore, performing cell counts is challenging, and so the mean gray value of the
DAPI stain (which stains the nuclei of all cells) was compared to the mean gray value of
the γH2A.X immunostain (which marks sites of double-stranded DNA breaks). This
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quantification methodology is not as robust and reproducible as performing cell counts
would be, and this may explain why the quantification for DNA damage foci in Atrx-null
cells treated with cPFTα is not significantly higher than DNA damage foci in Atrx-null cells
treated with only DMSO. However, this result does indicate that the loss of Atrx alone is
associated with the induction of genomic instability, and this instability is maintained or
even increased upon the loss of TP53 function. Furthermore, despite the maintenance of
DNA damage in these double null cells, their ability to survive in culture is retained at
levels comparable to controls – both of which are hallmarks of tumorigenic cells.
One advantage of this sequential in vitro system is that it models more realistically the
series of early events that may unfold in a cell undergoing tumorigenic transformation. We
know from previous literature that cells lacking Atrx expression alone do develop
characteristics of tumorigenic cells – like mitotic defects, mis-segregated chromosomes,
and DNA replication stress (Seah 2008; Ritchie 2008; Watson 2013). However, Atrx-null
cells both in vitro and in vivo also activate the TP53 response pathway, leading to apoptosis
(Seah 2008; Watson 2013). Thus, it is unlikely that a “single-hit” mutation in ATRX would
to lead to tumorigenic transformation in cells, supporting the requirement for a second
mutation to promote carcinogenesis. Our in vitro system models the sequential loss of Atrx
followed by TP53 inhibition, and we can see that this system does allow for increased
cellular survival despite the accumulation of DNA damage foci. However, a disadvantage
of this system is the use of a reversible drug to inhibit a specific protein’s function. Protein
inhibitors are notorious for having off-target effects and for not always generating
reproducible results. Cyclic Pifithrin-α is a more specific and less cytotoxic form of the
original non-cyclic drug Pifithrin-α (Zuco 2008); however, it is still a reversible inhibitor
of TP53 and may not produce as robust of a response as a more permanent and reproducible
inactivation of TP53 function would. Thus, a more efficient and specific system to
sequentially inactivate both ATRX and TP53 function would allow for a more robust and
reproducible response in vitro.

81

5.2.2

Simultaneous Loss of ATRX and TP53 Function in Mouse NPCs

The second in vitro system allowed for the simultaneous genetic silencing of both the Atrx
and Tp53 genes using adenovirus-CreGFP infected NPCs. A reduction in cellular viability
was identified, as expected, in Atrx-floxed ad-CreGFP infected NPCs in culture. Again, as
was similarly seen in the first in vitro system, Atrx/Tp53 double floxed cells infected with
ad-CreGFP demonstrated restored cellular viability. This result demonstrates that Atrx-null
NPCs are likely undergoing cell death via a TP53-dependent pathway, a result found
previously in embryonic cortical neurons in vivo (Seah 2008). Loss of both TP53 and
ATRX protein expression was therefore able to restore cellular survival, indicating TP53
activity as the main player in the reduction of Atrx-null cellular viability. Furthermore, the
maintenance of high cellular viability in all NPC genotypes infected with ad-GFP alone
indicates that neither adenoviral infection nor GFP expression affected cell survival on its
own.
Atrx/Tp53 double floxed cells infected with only ad-GFP show basal levels of DNA
damage foci, while infection of double floxed NPCs with ad-CreGFP leads to a
qualitatively significant enhancement in γH2A.X immunostaining throughout many cells
in culture, indicative of an increase in genomic instability in these double-null cells in
culture. Previous literature has identified that the loss of Atrx is associated with
dysregulation in DNA damage repair and/or with proper DNA replication, thereby leading
to the accumulation of DNA damage foci (Lovejoy 2012; Leung 2013; Watson 2013;
Clynes 2014). Thus, cells that have lost both ATRX and TP53 protein expression no longer
undergo apoptosis, but concomitantly acquire further genomic insult leading to massive
chromosomal instability. Enhanced cellular survival and accumulation of DNA damage are
two major hallmarks of cells undergoing tumorigenic transformation (Hanahan 2011),
indicating that the combined loss of ATRX and TP53 simultaneously may be sufficient to
drive NPCs into a tumorigenic state.
This second in vitro system is temporally different from the first system in that the
expression of both Atrx and Tp53 are lost simultaneously in cultured NPCs, rather than the
stepwise loss of ATRX and TP53 function described in the first system. This simultaneous
in vitro system may not as closely recapitulate genetic events that happen in vivo, as
82

typically patients will gain mutations in genes over time rather than acquire two “hits” at
the exact same time. However, the use of an adenovirus carrying Cre recombinase is a
much more robust and reproducible methodology in generating Atrx/Tp53 double-null
cells. Cells that fluoresce green are easily identified, and because the Gfp gene is tagged
onto the end of the Cre recombinase gene, we know that all green cells will also be
expressing Cre. The Cre gene is highly precise and efficient, thus enabling us to gain high
specificity and efficacy in recombining and silencing both floxed genes in NPCs in vitro,
as seen by the western blotting validation of ATRX and TP53 protein expression levels.
Enhanced robustness resulted in a much more profound visual increase in γH2A.X
immunostaining, indicative of a more intense induction in genomic instability in this
system.
Overall, both in vitro systems demonstrate two major phenotypic characteristics required
in order to define a cell as cancerous (Hanahan 2011). Firstly, carcinogenic cells display
changes, either genetic or epigenetic, to the so-called healthy genome (Hanahan 2011). This
condition is met in both systems, whereby excess genomic instability is demonstrated upon
the loss of both ATRX and TP53 function in cultured NPCs compared to controls.
Secondly, cells must exhibit an atypical survival advantage despite the presence of excess
DNA damage (Hanahan 2011). This condition is met in both systems whereby cells that
have lost only Atrx expression show significantly reduced cellular survival, whereas cells
that have lost both ATRX and TP53 function appear to have reduced apoptosis, and thus
restored cellular survival, similar to levels of control cells along with enhanced genomic
instability. Thus, these double-null NPCs in culture demonstrate abnormal survival in
culture compared to their Atrx-null counterparts in vitro, indicating that these cells have
acquired a survival advantage. I conclude that loss of ATRX and TP53 function in vitro,
either sequentially or simultaneously, is capable of inducing characteristic phenotypes
common to carcinogenic cells.

83

5.2.3

Future Directions for In Vitro Model Systems of Glioma

Although the previously described in vitro systems appear to have acquired important
characteristics of tumorigenic cells upon the loss of both ATRX and TP53 function, there
are many other characteristic phenotypes common to carcinogenesis that would be
interesting to examine in these cells. Firstly, cellular viability and survival was measured
in the present study, but proliferation was not. Examination of cell growth and proliferation
over time, or monitoring for the presence of neurospheres, would indicate whether
ATRX/TP53 double-null cells demonstrate enhanced proliferation in vitro. Additionally,
cancerous cells will commonly demonstrate increased invasion or migration phenotypes,
as tumorigenic cells typically migrate throughout and invade healthy tissues in order to
spread and metastasize (Hanahan 2011). Placing Atrx/Tp53 double-null NPCs in a
Transwell migration and/or Matrigel invasion assay to determine whether these cells show
higher levels of these phenotypes would be quite interesting, as gliomas in humans tend to
have a highly invasive and infiltrative nature (Marumoto 2012). Additionally, tumorigenic
cells in vivo are often capable of activating angiogenesis, in order to stimulate blood vessel
growth to provide the growing tumour mass with a source of nutrients and oxygen as well
as a source for depositing metabolic waste and carbon dioxide (Hanahan 2011). Injection
of Atrx/Tp53 double-null NPCs grown in culture back into nude, immuno-compromised
mice would indicate whether these tumour-like NPCs are capable of attaching to tissue in
vivo and continue growing, while at the same time promoting blood vessel growth towards
the emerging tumour mass.
Finally, as was discussed in the introduction, glioma and PanNET patients with tumours
carrying mutations in ATRX or harbouring a loss of ATRX staining via
immunohistochemistry show a significant association with the activation of the alternative
lengthening of telomeres (ALT) phenotype (Heaphy 2011; Jiao 2011; Schwartzentruber
2012; Abedalthagafi 2013). As well, loss of Atrx alone is associated with an increase in
telomere dysfunction, DNA damage foci at the telomeres, and telomere fusions (Watson
2013), and ATRX loss of function in somatic cell hybrids also segregated with the activation
of the ALT pathway (Bower 2012). These results are consistent with ATRX playing a role
in telomere maintenance and acting as a repressor of ALT in vivo. It will be important in
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the future to determine the presence of ALT in our culture systems using telomere-FISH to
identify whether prolonged ATRX loss of function in vitro could promote excessive
telomere recombination.

5.3

In Vivo Analysis of Atrx deletion in the mouse brain

Previous studies have characterized several phenotypes upon the loss of Atrx expression
both in vivo and in vitro (reviewed in Bérubé 2011). Many characteristics of Atrx-null cells
are shared by tumorigenic cells – like excessive DNA replication stress, mitotic defects,
chromosomal fusions and misseggregation (Seah 2008; Ritchie 2008; Watson 2013) – and
thus it was not surprising that mutations in ATRX were found within a significant subset of
gliomas (Jiao 2011; Schwartzentruber 2012; Liu 2012; Kannan 2013). Examination of
glioma patient databases, as well as analysis of genetic and molecular changes in vivo upon
the loss of ATRX expression, may provide evidence to decipher whether mutations in ATRX
act as drivers or as passengers of tumorigenesis.

5.3.1

Dysfunction of ATRX in Glioma Patients

Analysis of ATRX expression in a large cohort of glioblastoma multiforme patient samples
from The Cancer Genome Atlas database indicated that patients harbouring low expression
levels of ATRX demonstrated a significantly earlier age of diagnosis as well as a trend
towards better overall survival compared to tumours with normal or high levels of ATRX.
These results have been both supported and opposed in the literature. For example,
mutations in ATRX were associated with similar findings (earlier age of diagnosis and better
overall patient survival) in patients with pancreatic neuroendocrine tumours (PanNETs;
Jiao 2011). As well, ATRX loss defined a sub-population of astrocytic tumours with a more
favourable prognosis demonstrating a time to treatment failure of 55.6 months versus 31.8
months in ATRX wildtype tumours (Weistler 2013). Other studies found no correlation
between ATRX status and age of diagnosis or patient prognosis, but this may be due to small
sample sizes or the specific tumour populations studied (Abedalthagafi 2013). Oppositely,
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further studies of ATRX loss in panNETs have demonstrated a correlation with reduced
time of relapse-free survival and decreased time of tumour-associated survival (Marinoni
2014). While it is still unclear how ATRX mutations influence patient progression, it is
likely that ATRX mutation or expression status may be beneficial in defining discrete
subsets of gliomas associated with treatment response and patient survival.
Furthermore, examination of copy number variation data for glioma cell lines on the
Catalogue of Somatic Mutations in Cancer (COSMIC) database identified an association
between amplification of the ATRX locus and increased genomic instability and whole
chromosome gains/losses genome-wide. Unfortunately, as there was no mRNA expression
data to correlate with the CNV data, we had to rule out cell lines originating from female
patients as we would not be able to tell if the ATRX locus from the active or inactive
chromosome was amplified. Additionally, even in males harbouring amplification of the
ATRX locus on the X chromosome, without expression analysis we are unable to know
whether these cells are gaining functional or non-functional copies of the ATRX gene.
Nevertheless, glioma cell lines harbouring excessive copies of the ATRX locus
demonstrated significantly more genomic instability, as quantified by increased numbers
of abnormal genomic segments, as well as a trend towards increased whole chromosome
events. We know from previous literature that not only does ATRX loss lead to cellular
dysfunction, but overexpression of ATRX is also associated with severe developmental and
cellular deficits (Bérubé 2002). Increased ATRX expression in transgenic mice led to
abnormal growth and organization of the ventricular zone in E10.5 embryos, as well as
growth retardation, neural tube defects, and a high incidence of embryonic death (Bérubé
2002). Therefore, ATRX dosage is likely crucial for proper neuronal development, and thus
overexpression of ATRX may also be associated with phenotypes relative to cancer
development, like enhanced genomic instability.

5.3.2

Atrx Loss in the Brain is Associated with Alterations in Cancer-Related
Signalling Pathways

ATRX is a known chromatin-associated protein, using its N-terminal ADD domain to direct
binding to sites of heterochromatin (Bérubé 2011; Dhayalan 2011; Argentaro 2007). ATRX
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can be directed to specific sequences within the genome via histone modifications or
protein recruitment (Dhayalan 2011; Nan 2007), and these sites are typically GC-rich and
repetitive regions, like telomeres and G-quadruplexes (Law 2010). Given the roles of
ATRX at chromatin, it comes as no surprise that ATRX loss leads to alterations in gene
transcript levels both in cells undergoing mitosis and in non-dividing cells (Levy 2008).
For example, analysis of the Atrx-null neonatal mouse forebrain identified consistent
downregulation of ancestral pseudoautosomal region genes (Levy 2008; Levy 2014), as
well as differential expression of many imprinted genes (Kernohan 2010; Kernohan 2014).
Recent evidence indicates that at a subset of genes, ATRX is capable of binding G-rich
secondary DNA structures called G-quadruplexes (G4) to enable bypass of transcriptional
machinery and mRNA elongation (Levy 2014). As well, ATRX has been shown to be
involved in chromatin looping, enabling the contact between distant enhancers and
promoters in order to encourage gene expression (Kernohan 2014). Thus, although the full
range of the ability of ATRX to affect gene expression changes has not yet been elucidated,
it is clear that the loss of Atrx expression is associated with alterations in gene expression
through both chromatin looping and through the resolution of secondary DNA structures.
Microarray analysis of control versus Atrx-null neonatal mouse forebrains identified
numerous significant gene expression changes. GO term analysis for these genes indicated
a large number as being involved in stem cell pluripotency, the WNT pathway, and
cardiogenesis. Further literature searches identified several candidate genes within these
GO pathways as known effectors of glioma initiation and progression. Real time PCR
analysis validated the upregulation of many gene targets demonstrated in the literature to
be associated with cellular characteristics common in glioma, like cellular migration and
invasion (Cxcl2, Mmp2, Mmp14, Igfbp2, Gsn, Lox, Mdk, and ErbB3), epithelial-tomesenchymal transition (EMT; FoxC1, FoxC2, S100A11, and Ahnak), and the WNT
pathway (Wnt5a, Wnt7b, and Fzd7). Consistent upregulation of these targets indicates that
Atrx loss in the surviving differentiated neurons of the neonatal mouse cortex may lead to
the development of a cellular environment conducive of tumorigenesis.
One gene, ErbB3, was further validated by in situ hybridization and western blotting and
was shown again to be upregulated in the Atrx-null neonatal mouse forebrain at both the
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mRNA and protein levels. The ERBB3 protein is a member of the epidermal growth factor
receptor (EGFR) family and lies upstream of a signalling cascade known to promote
cellular migration, invasion, protein synthesis, and cell growth (Kim 1998; Kamalati 2000;
Jones 2006). Dysregulation in ERBB3 protein has also been shown in gliomagenesis, as
overexpression of ERBB3 is associated with pilocytic astrocytoma progression (AddoYobo 2006) and radiation-induced glioblastomas (Donson 2007), and prominent
expression of ERBB3 was seen in CD-133 positive putative glioblastoma tumour stem cells
(Duhem-Tonnelle 2010). Western blots for p-AKT also showed upregulation in the
presence of upregulated p-ERBB3 indicating enhanced signalling through downstream
oncogenic pathways. The consistent upregulation of ErbB3 mRNA and p-ERBB3 protein
in our system indicates that the loss of Atrx expression in cells of the neonatal mouse cortex
induces the expression of genes known to promote glioma development and increase
signalling through oncogenic pathways, therefore creating a cellular environment
conducive to tumorigenesis.

5.4

In Vivo Modelling of Combined Atrx and Tp53 Loss

Recent patient studies have indicated a common and consistent overlap between mutation
of ATRX and TP53 in a significant number of gliomas (Jiao 2011; Schwartzentruber 2012;
Kannan 2013), indicating that the combined loss of ATRX and TP53 function in vivo may
enable cells to acquire tumorigenic characteristics while also avoiding cell death. This
combinatorial genetic mutation may thus be the driving force of tumorigenesis in a specific
subset of glioma patients.
The in vivo model developed in the present study used mice heterozygous for Tp53, along
with heterozygosity for Atrx in the brain. Tp53 heterozygosity in mice is known to confer
a low spontaneous tumour incidence up to approximately 12 months of age (Harvey 1993;
Donehower 1996), with about half of the heterozygous mice developing tumours by 18
months of age (Donehower 1996). This is because the mice retain a single, functional copy
of the Tp53 allele and therefore a second mutagenic event must occur to remove the
remaining Tp53 allele in order for cancer to develop (Harvey 1993). Tp53 heterozygous
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mice preferentially develop osteosarcomas, lymphomas, and soft-tissue sarcomas, which
affect the supporting tissue (fat, blood vessels, nerves and ligaments) surrounding the body
organs (Donehower 1996). These mice are useful in carcinogenesis studies with chemicals
or additional mutagenic hits to study whether additional mutations can drive tumorigenesis
in these mice at an enhanced rate. In the present study, CNS-specific loss of one Atrx allele
was performed to identify whether combined Atrx/Tp53 loss could drive tumorigenesis in
the mouse CNS before developing tumours throughout the body.
Current work in our lab has identified that Nes-Cre+ Atrx+/- mice display reduced growth
and decreased overall weight compared to wildtype mice, associated with reduced levels
of circulating IGF-1 (unpublished data). Thus, it was not surprising to find that both the
Atrx heterozygous and double heterozygous mice showed these same characteristics in the
present study. Additionally, as explained above, Tp53 heterozygous mice have been shown
to succumb to their tumours around 12-18 months of age (Donehower 1996; Harvey 1993),
and these results were reiterated in the present study in which the Tp53 heterozygous and
double heterozygous mice demonstrated a similar mean survival of around 500 days, or 15
months. These results indicate that heterozygosity of Atrx in the mouse CNS beginning at
E11.5, as driven by Nes-Cre expression, is likely driving the reduced weight in the double
heterozygous mice, while heterozygosity of Tp53 is likely responsible for the reduced
survival of these mice. Combined heterozygosity of Atrx and Tp53 does not appear to
further affect overall weight or survival in these mice.
Both the Tp53 heterozygous and double heterozygous mice developed internal lesions
consistent with previous reports. These mice harboured tumours in the soft tissue of one or
more organs including the intestines, liver, kidneys, and thymus, with a few even
developing tumours in the hind limbs. As the double heterozygous mice did not
demonstrate reduced survival compared to the Tp53 heterozygous mice alone, it is likely
that these internal lesions are the cause of the early death of these mice. Future examination
of the brain tissue of these mice will reveal if abnormal proliferation, increased DNA
damage and tumour formation occur.
My studies have shown that combined loss of ATRX and TP53 function, both sequentially
and simultaneously, was capable of increasing cell survival and genomic instability in
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cultured NPCs; however, the phenotypic effects were relatively slight. This evidence
indicates that perhaps ATRX loss is capable of driving tumorigenic phenotypes, but this loss
may require further time or additional mutational hits to fully drive cells into a tumorigenic
state. For example, the large majority of glioma patient studies have indicated a link
between ATRX mutation, or a loss of ATRX immunostaining, and the presence of the
alternative lengthening of telomeres phenotype (Jiao 2011; Schwartzentruber 2012; Liu
2013). As mouse telomeres are significantly longer than human telomeres, perhaps the loss
of Atrx in the mouse is not leading to ALT activation as it does in human cells. The use of
a mouse line harbouring already shortened telomeres may help in discovering whether the
Atrx loss drives gliomagenesis through telomere destabilization and ALT activation.
Furthermore, a more specific loss of Tp53 in the mouse would bypass any non-specific
tumour development and allow for precise examination of combined Atrx and Tp53 loss in
the brain.

5.4.1

Future Directions for In Vivo Modelling of Combined Atrx/Tp53 Loss

Further experiments looking for markers of overproliferation and stem-cell characteristics
would indicate whether heterozygosity of Atrx and Tp53 in the mouse brain could lead to
tumorigenesis. For example, immunostaining for the presence of cell proliferation markers,
like Ki67, or cell cycle analysis dyes, like propidium idodide (PI), would indicate regions
of the mouse brain showing enhanced proliferation – a hallmark of tumorigenic cells. As
well, immunostaining for γH2A.X, a marker of double stranded DNA breaks, would
identify areas of the mouse brain harbouring increased DNA damage, indicative of
amplified genomic instability. Furthermore, as these heterozygous mice are mosaic for the
loss of Atrx due to random X-chromosome inactivation, immunostaining for both ATRX
and TP53 would detect whether cells that harbour enhanced genomic instability and/or
proliferative capacity are also negative for both ATRX and TP53 proteins. This
immunostaining would also further validate the mouse genotypes and indicate whether the
double heterozygous mice show expansion of neurons harbouring a loss of both ATRX and
TP53.
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Other members of the lab are now developing a new mouse model of inducible Atrx and
Tp53 inactivation in neural stem cells and astrocytes. This mouse carries floxed alleles for
both Atrx and Tp53 and also includes the Cre recombinase gene under the control of the
Slc1a3 or Glast3 promoter, which directs recombination of Atrx and Tp53 specifically in
the glial stem cells and radial glia of the mouse brain (Mich 2014). As well, this mouse
model harbours a tamoxifen-inducible Cre recombinase gene under the control of the
Slc1a3 promoter, allowing for a more specific spatial and temporal deletion of Atrx and
Tp53 expression. This mouse model will drive Atrx and Tp53 loss specifically in glial stem
cells. The use of a more specific mouse model will allow for the direct and robust
inactivation of both Atrx and Tp53 in the glial stem cells of the brain, which are potential
cells of origin for GBM, in order to determine whether these two mutagenic hits can lead
to glioma development in the mouse brain.

5.5

Conclusions

In conclusion, combined loss of both ATRX and TP53 function in vitro leads to increased
NPC survival and enhanced genomic instability (Fig. 5.1). Furthermore, Atrx loss in the
neonatal mouse brain resulted in a consistent transcriptional upregulation of cancer-related
genes involved in migration/invasion, EMT, and the WNT pathway – cellular pathways
common in oncogenic cells (Fig. 5.1). Examination of available online data indicated that
low expression of ATRX in GBM patients was associated with an earlier age of diagnosis
and trended towards better overall survival compared to patients demonstrating normal or
high expression of ATRX. Additionally, dosage of the ATRX locus appears to affect
genomic instability, as glioma cell lines harbouring a gain of the ATRX locus demonstrated
enhanced DNA damage and an increased number of whole chromosome gains and losses.
Finally, an in vivo system was created that combined loss of Atrx and Tp53 deficiency.
Future studies will determine whether these mice develop cellular abnormalities or tumors
in the brain. The use of mouse models with spatiotemporal control of Atrx and Tp53
expression will provide a more robust and precise model in which to study glioma
development in vivo.
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Figure 5.1 Visual summary of the conclusions from this thesis. Cells harbouring intact
ATRX and TP53 expression (A) demonstrate undamaged double stranded DNA and
correct chromosome architecture within the nucleus (light blue), along with basal levels
of ERBB3 (orange shapes) and AKT (green hexagons) protein expression in the
cytoplasm of the cell (dark blue). Upon mutation of ATRX or loss of ATRX expression
(B), DNA acquires a significant amount of double stranded breaks, marked by the
histone γH2A.X (red lines). ATRX loss is also associated with an increase in both
ERBB3 and phosphorylated (yellow circles) ERBB3 protein expression, along with a
subsequent increase in phosphorylated AKT within the cytoplasm. The presence of
significant genomic instability leads to the activation of TP53 (red stars) and the
subsequent initiation of apoptosis (C). Cells double-null for ATRX and TP53 survive,
and thus cell progeny harbour excessive genomic instability and chromosomal
abnormalities within the nucleus leading to proliferative advantage and gliomagenesis
(D).
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